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ICRU  International Commission on Radiation Units & Measurements 
HVL  Half value layer 
Kerma  Kinetic energy released per unit mass 
keV  Kiloelectron-volt 
kV  Kilovolt 
kVp  Kilovolt peak 
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RERF  Radiation Effects Research Foundation 
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1 Introduction and objectives 
Breast cancer is the most common cancer in women worldwide, both in terms of number of 
new cases, (23% out of all cancers) and malignancy (14% of all cancer deaths) (1, 2). In 
Norway breast cancer among women comprises more than 20% of all female cancer cases, 
and it is the third most common cause of cancer death (3). In 2008 the age-standardized 
(world) incidence rate (ASR) for breast cancer was 72.9 per 100 000 person-years for 
women in Norway (year 2010: 73.0) (4). The ASR for breast cancer worldwide for women 
was 39.0 per 100 000 person-years, ranging from 19.3 per 100 000 person-years for 
women in Eastern Africa to 89.9 per 100 000 person-years for women in Western Europe 
(2). The cancer incidence in Norway is thus high compared to many other countries. 
 
Mammography is an x-ray examination of the breast and has been conducted for a 100 
years (5). Further, mammography is the only proven method capable of screening, i.e. to 
identify non-palpable breast cancer in women without clinical signs who may be at 
increased risk of early stage breast cancer (6-8). In Norway an organized screening 
program, the Norwegian Breast Cancer Screening Program (NBCSP), which is part of the 
public health care system in Norway, started up as a trial project in 1995/1996, and was 
gradually implemented in the time period 1996-2005. All women in Norway aged 50-69 
years are invited to a screening examination biennially, and this has resulted in an increase 
in the number of mammography examinations of 70% (9). The program complies with the 
principles of early disease detection set by the World Health Organization (WHO), and the 
main goal is to reduce disease-specific morbidity and mortality through early detection 
(10-17). The mortality reduction is 16-36% (Europe: 25-31%) in invited versus non-invited 
women in service screening programs, while in screened versus non-screened women the 
reduction in mortality is 24-48% (Europe: 38-48%) (18-20). In the NBCSP a mortality 
reduction of 43% has recently been reported (21), in other words in accordance with other 
screening programs. The reduction in mortality is mainly the result of early detection of 
subtle soft-tissue masses and microcalcifications, which may be early signs of breast 
cancer, and improved treatment (22, 23). Early detection, as can be achieved with 
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mammographic screening, thus, is important, and screening as a method seems to work 
presuming high quality standards in every part of the program. 
 
Overall, mammography is one of the most technically challenging of all radiographic 
examinations (24-26). Thus quality control is of the utmost importance in order to obtain 
adequate image quality and keep the radiation doses “as low as reasonably achievable” 
(ALARA principle). In 1993 the European Commission published the first guidelines for 
quality assurance in mammography screening, and these guidelines has improved the 
quality of breast screening, the diagnosis and treatment of breast cancer, and reduced the 
differences in the quality of care of breast disease among member states of the European 
Union (27, 28). Further, it contributed immensely to the success of the breast screening 
projects in Europe. In connection with the start-up of the NBCSP a quality assurance 
manual was published and later revised (1998 and 2003) (25). It has been implemented in 
all 16 breast clinics in the NBCSP. The manual is based on the European Guidelines, the 
WHOs 10 principles of early disease detection, policies, and experiences from randomized 
trials (16, 27-32).  
 
Prior to the start-up of the trial project the Norwegian Radiation Protection Authority 
(NRPA) had acquired expertise in the field of technical quality control in mammography 
(33-37). With the start-up of the NBCSP the NRPA was given a special mandate: the 
NRPA was to conduct technical quality control, be responsible for optimization of image 
quality/radiation dose and be responsible for training in technical quality control, image 
quality and radiation principles in mammography. In the NBCSP the NRPA conduct 
annual technical quality controls, so-called status controls, and through these annual 
technical quality controls data on technical performance, radiation dose and image quality 
are collected (25, 38). In addition, dose surveys for the women attending the NBCSP have 
been conducted in accordance with the mandate given to the NRPA, which is stated in the 
quality assurance manual for the NBCSP (25).  
 
The NRPA base its radiological protection on the three principles of the International 
Commission on Radiological Protection (ICRP): Limitation, optimization, and justification 
(39). The principle of optimization implies that all exposures shall be as low as reasonably 
achievable with respect to radiation dose. In order to fulfill this criterion surveys of the 
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radiation dose for the women examined in the NBCSP have been conducted (40-42). With 
the change from screen film mammography (SFM) to full-field digital mammography 
(FFDM), which took place in the time period 2000-2011, it was necessary to examine how 
different manufacture/models of SFM and FFDM systems operate in a population-based 
screening programme with respect to the mean glandular dose (MGD). And if there are 
differences, can they be explained by differences in technology and/or exposure factors? 
Further, after the transition from SFM to FFDM it was necessary to establish a new 
diagnostic reference level (DRL) for the FFDM units. The DRL is a pragmatic tool used 
for optimizing radiation doses for radiologic examinations (43, 44). In the regulations it is 
demanded that a DRL is established in order to serve as a comparison between different 
units used for the same type of examination (45). That said, optimization is not only a 
question about optimizing the radiation dose, but also about optimizing the image quality 
(46). Therefore, when establishing a new DRL it was also of interest to evaluate the image 
quality for the units of different manufacture/models to see if any differences occur, and in 
addition investigate how the image quality and MGD relate to each other for different 
manufacture/models. Further, the parameters that are used to estimate the MGD are 
encumbered with uncertainties. It was needed to address these uncertainties in order to 
estimate the uncertainty inflicted for the estimated MGD. 
 
The principle of justification implies that no practice involving exposure to ionizing 
radiation shall be adopted unless it produces a net benefit. The reduced mortality from the 
disease and breast conserving treatment, instead of mastectomy, are considered the main 
benefits from breast cancer screening (14, 19, 20, 47-54). Another advantage is the 
improved quality assurance of the diagnostic chain (54). The disadvantages are a) the false 
positives (a woman receiving a positive test result from screening, when in fact the result 
was negative), b) the interval cancers (a cancer that occurs between two screening rounds), 
c) the overdiagnosis (the diagnosis of "disease" that will never cause symptoms or death 
during a patient's lifetime), and d) the potential risk of developing cancer caused by the 
radiation dose. In addition to an evaluation of the breast mortality reduction, it is also 
important to evaluate the other pros and cons listed above. Ionizing radiation is a risk 
factor for breast cancer (55). It is therefore important to evaluate the potential risk of 
radiation-induced breast cancers due to an organized mammographic screening program as 
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performed in Norway, in order to weigh the pros and cons in a cost-benefit analysis and in 
order to examine if the operation of the NBCSP can be justified. 
 
The overall objective of this thesis is to study the trends and possible dose savings in the 
transition from analogue to digital mammography in a screening setting, refine the 
dosimetric method and assess the uncertainties in an assessment of mean glandular dose to 
women, examine technology differences between different manufacture/models that make 
a common national DRL less feasible, identify an image quality parameter that can be used 
along with dose to assess performance for the different manufacture/models and to 
establish well founded risk estimates as an input in the cost-benefit discussion in a 
screening program. 
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2 Scientific background 
2.1 Dosimetry 
2.1.1 Definition of kerma and absorbed dose 
Kerma ("kinetic energy released per unit mass") is defined as the initial kinetic energy of 
all secondary charged particles liberated per unit mass at a point of interest by uncharged 
particles (56). If ψ (J m-2) is the energy fluence of monoenergetic photons passing normally 
over an area in an absorber, then for a polyenergetic x-ray beam the air collision kerma can 
be written as 
ܭ௖ǡ௔௜௥ ൌ ׬ ቀఓ೐೙ఘ ቁ௔௜௥
ஶ
଴ ɗ௛௩݀ሺ݄ݒሻ ൌ ቀ
ఓ೐೙
ఘ
തതതതቁ
௔௜௥
ɗ   (1) 
where the mass energy absorption coefficient in air is averaged over all photon energies in 
the x-ray spectra,ቀఓ೐೙ఘ
തതതതቁ
௔௜௥
 (57). 
For low atomic number materials (such as air) the production of bremsstrahlung is 
negligible, and the mass energy transfer coefficient, which is the fraction of the mass 
attenuation coefficient which contributes to the production of kinetic energy in the charged 
particles, ቀఓ೟ೝఘ ቁ, is equal to the mass energy absorption coefficient, ቀ
ఓ೐೙
ఘ ቁ (58).  
 
The energy deposited per unit mass of the medium is known as the absorbed dose. It is a 
very useful quantity for the prediction of biological effects and is the basic physical 
quantity in radiation biology, radiology and radiological protection (59). Further, it is used 
for all types of ionizing radiation. The absorbed dose, ܦ, is defined in International 
Commission on Radiation Units and Measurements (ICRU) Report 60 as  
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ܦ ൌ ௗఌതௗ௠          (2) 
where ݀ߝҧ is the mean energy imparted to matter of mass ݀݉ after interaction with ionizing 
radiation. The SI unit of absorbed dose is J/kg and this unit has been assigned the name 
gray (Gy).  
 
For a given material (for instance tissue or air) and radiation field, absorbed dose and 
kerma are numerically equal, when secondary electron equilibrium is established. At the 
low energies used in mammography, charged particle equilibrium is fulfilled in both the 
dosemeter and the absorbing medium (56, 60). 
 
The absorbed dose in tissue, ܦ௧௜௦௦௨௘, is related to the absorbed dose in air, ܦ௔௜௥, by (58): 
ܦ௧௜௦௦௨௘ ൌ ܦ௔௜௥
ቀഋ೐೙ഐ ቁ೟೔ೞೞೠ೐
ቀഋ೐೙ഐ ቁೌ೔ೝ
       (3) 
where ቀఓ೐೙ఘ ቁ௧௜௦௦௨௘ and ቀ
ఓ೐೙
ఘ ቁ௔௜௥ are the mass energy absorption coefficients in tissue and 
air, respectively. 
 
In mammography the air kerma free-in-air on the central axis of the x-ray beam at a 
specific distance from the focal spot is measured, employing a calibrated ionization 
chamber and electrometer, and can be used to evaluate the entrance dose (entrance surface 
air kerma (ESAK)) (28, 60). The chamber should have a flat energy response for the kV 
range applied in mammography (60). 
 
2.1.2 Definition of equivalent dose and effective dose 
The probability of cancer incidence is found to depend not only on the absorbed dose, but 
also on the type and energy of the radiation depositing the dose (61). The ICRP therefore 
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recommends that for radiological protection purposes the organ dose should be weighted 
for the radiation quality. Equivalent dose is defined by the ICRP as absorbed dose 
multiplied by a unitless radiation weighting factor (wR) that accounts for differences in 
biologic effectiveness between different types of radiation. The unit of equivalent dose is 
J/kg and this unit has been assigned the name sievert (Sv) (for x-rays: 1 Gy = 1 Sv = 1 
J/kg). Effective dose, which is also measured in Sv, is defined by the ICRP as the 
equivalent dose multiplied by a unitless tissue weighting factor (wT) that accounts for 
inherent differences in tissue radiosensitivity, and then summing the contributions for all 
specified tissues. Effective dose is used to compare the impact of different exposure 
situations from a radiation protection point of view. Risk estimates, however, should be 
based on the absorbed dose in the organ (62). 
 
2.1.3 Monte Carlo simulations and mean glandular 
dose (MGD) 
It is of interest to estimate the average dose to the breast tissue rather than the entrance 
dose. It is the amount of radiation dose delivered to the proliferative tissue or stem cells 
within the terminal ductolobular units that is of importance, since this tissue is considered 
to be the most sensitive to radiation (63-66). As a result, there is agreement that the 
average dose to the glandular tissue (MGD) is the most appropriate dosimetric quantity to 
predict the risk of carcinogenesis (66, 67).  
 
Some assumptions are made in order to determine the MGD: a) that compression is 
applied, b) that there is an outer layer of adipose tissue surrounding the breast, and c) that 
the breast contains a uniform mix of adipose and glandular tissue (68). The dose to the 
whole breast strongly depends on: a) the x-ray spectrum, b) the breast composition and c) 
the breast thickness (60). The MGD cannot be measured directly, but needs to be estimated 
from the measured incident air kerma multiplied by conversion coefficients, based on 
simulations of photon transport in tissue; so-called Monte Carlo techniques (60, 67-69). In 
the dose estimations that are included in Papers I-V the method and conversion factors 
used proposed by Dance et al. have been applied (41, 42, 70).  
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Different conversion coefficients have been published throughout the years, but the model 
that is currently used when estimating the MGD in the NBCSP is the one published by 
Dance et al. (41, 66, 70-73): 
ܯܩܦ ൌ ܭ௔ǡ௜݃ܿݏ        (4) 
Here ܭ௔ǡ௜ is the incident air kerma on the compressed female breast. The factors ݃, ܿ and ݏ 
are conversion factors: ݃ is the conversion coefficient from air kerma to MGD (41), ܿ is 
the correction factor for any difference in breast composition from 50% mammographic 
density (42) and ݏ is the correction factor for any difference in the x-ray spectrum from 
that produced by an x-ray tube with a Mo target and a Mo filter (42, 70). 
 
In order to estimate the conversion factors a compressed breast phantom is used (42). The 
phantom has the shape of a cylinder of semicircular cross section, a diameter of 16 cm, a 
0.5 cm thick adipose surface layer, and a central region. Originally, conversion factors 
were obtained through simulations of a central region composed of 50% adipose and 50% 
glandular tissues by weight (50% glandularity) (41). The conversion factors were then 
extended to breasts of varying breast thickness (2-11 cm), varying glandularity (varied 
between 99.9% adipose tissue/0.1% glandular tissue (0.1% glandularity) and 100% 
glandular tissue (100% glandularity) in steps of 25% glandularity) and for a wider range of 
mammographic x-ray spectra (42). The radiation dose within the breast decreases rapidly 
with increasing depth (60).  
 
A Monte Carlo program simulated each photon that started at the focal spot of the x-ray 
tube and followed its path from region to region through the model until all the energy of 
the photon was absorbed or it left the system (74). All of the energy deposited in each 
region of the model was recorded. The energy deposited in the central region of the breast 
was divided between adipose and glandular tissues in accordance with the interaction 
probabilities in the two tissue types. Because the technical parameters and imaging 
protocols have changed over the years, new conversion factors have had to be established 
(41, 42, 66, 70, 71, 75-78).  
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2.2 Image quality 
In mammographic screening high image quality at a low dose to the breast is crucial, and 
therefore the technique needs to be optimized (60, 79, 80). 
2.2.1 Efficacy of diagnostic imaging 
A hierarchical model of the efficacy of diagnostic imaging was proposed by Fryback and 
Thornbury in 1991 (81, 82). Level 1 concerns technical quality of the images, Level 2 
addresses diagnostic accuracy associated with interpretation of the images, Level 3 focuses 
on whether the information produces change in the referring physician’s diagnostic 
thinking, Level 4 concerns effect on the patient management plan, Level 5 measure effect 
of the information on patient outcome, and at Level 6 analyses examine societal costs and 
benefits of a diagnostic imaging technology. These can be used as a guiding principle in 
the evaluation of medical imaging systems (83). Increases in technical image quality 
(Level 1) will not guarantee improvements at higher levels due to improvements in 
technical image control (for instance patient outcome) (81). Estimations of the dose and 
estimation of the image quality, as conducted in Papers I-IV, are part of Level 1 in this 
hierarchy of six levels of diagnostic efficacy.  
 
2.2.2 Contrast  
Both low and high contrast resolution is a requirement for the visualization of tumor 
masses and characterization of microcalcifications, respectively (84). From a technical 
point of view low and high contrast resolution can be measured by noise characteristics 
and use of contrast detail phantoms (84). 
 
Given a tissue of thickness t (Figure 1) and linear attenuation coefficient μ1 (the 
background signal) containing an embedded block of “target” tissue of thickness x (the 
attenuating object) and linear attenuation coefficient μ2. The contrast C is defined in terms 
of the image distribution functions I1 and I2, which give the energy absorbed per unit area 
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of the receptor in the background and in the attenuating object (85, 86). The contrast can be 
defined as (86): 
ܥ ൌ ூభିூమூభ ൌ
ሺଵି௘௫௣ሾሺఓభିఓమሻ௫ሿሻ
ଵାோ       (5) 
where R is the scatter-to-primary ratio. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Simple model used for the estimation of contrast. Given a tissue of thickness t 
and linear attenuation coefficient μ1 (the background signal) containing an embedded block 
of “target” tissue of thickness x (the attenuating object) and linear attenuation coefficient 
μ2.  
 
 
The x-ray attenuation coefficients of normal breast tissue and cancer are similar, and 
therefore the differences in transmission are small (Figure 2). This causes difficulties when 
it comes to separating normal breast tissue from cancer tissue. As the energy increases the 
inherent contrast for both tumors and microcalcifications falls. The small difference in x-
ray attenuation between glandular tissue and cancer tissue calls for dedicated equipment, 
dedicated exposure parameters, quality control, and optimization regimes. 
 
In order to discriminate between very similar soft tissues (fat, parenchyma etc.), low kV x-
rays are required in mammographic examinations (87). This will result in an increased 
radiation dose, mainly higher skin doses, but at the same time higher subject contrast is 
 
1P  2P x t 
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achieved (88). Dedicated x-ray tubes for mammography are operated at 28 kVp or less, 
where the photoelectric cross section dominates over the Compton cross section, and 
makes the largest contribution to the total cross section (60, 84, 89). Due to the fact that the 
energy transfer from scattering processes in the mammographic energy range is small, the 
photoelectric cross section also provides the difference between the mass energy 
absorption coefficients for adipose and glandular tissue (60). The major factors which 
emphasize photon absorption differences in tissue (subject contrast) are kV, linear 
attenuation coefficient, and tissue thickness.  
 
 
 
Figure 2. Mean values of the linear attenuation coefficients (μ) of fat (adipose tissue (A)), 
fibroglandular tissue (B) and tumor (infiltrating ductal carcinoma (C)) in the breast as a 
function of photon energy (measured in kiloelectron-volt (keV)). The linear attenuation 
coefficient describes the attenuation properties of a specific material at a specific x-ray 
energy (58). Figure reproduced from Johns and Yaffe (90) with permission. 
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2.2.3 Noise 
The two major contributors to noise in the radiographic image are statistical fluctuations in 
the number of x-ray photons detected per unit area (quantum noise), and fluctuations due 
to the properties of the image receptor and display system. The quantum noise arises from 
fluctuations in the energy absorbed by the receptor. A total of three components are 
assumed to make up the noise: a) electronic noise, b) quantum noise, and c) structural 
noise. The standard deviation in the image is given as  
ߪ ൌ ൫ߪ௘ଶ ൅ ߪ௤ଶ ൅ ߪ௦ଶ൯଴Ǥହ       (6) 
Where ߪ௘, ߪ௤ and ߪ௦ are the standard deviation terms representing the electronic noise, 
quantum noise and structural noise, respectively (91). Electronic noise is an additive 
source, independent of x-ray exposure, and may be written as ߪ௘ ൌ ݁. Quantum noise 
scales with the square root of the air kerma, and may be written as ߪ௤ ൌ ݍܭ଴Ǥହ, where ݍ is 
some coefficient. Structured noise results from factors specific to a given detector, and the 
signal from the different structured noise sources is amplified by the x-ray signal used and 
is therefore written as ߪ௦ ൌ ݏܭ. 
 
2.2.4 Signal-to-noise ratio (SNR) 
Diagnostic information should be obtained with the minimum possible absorbed dose (88). 
The aim is to predict the x-ray energy which gives the highest signal-to-noise ratio (SNR) 
for the least amount of absorbed dose. SNR is defined as 
ܴܵܰ ൌ ۃ௡೏ۄඥۃ௡೏ۄ         (7) 
where ۃ݊ௗۄ is the average number of x-rays used to form the image by interacting with the 
detector, and this number will fluctuate from location to location with a standard deviation 
of ߪ ൌ ඥۃ݊ௗۄ (92). This fluctuation is referred to as quantum noise. SNR indicates the 
quantum noise limited region of operation (93). Maximum SNRs per unit mean absorbed 
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dose ranges from 16-23 keV, and therefore suitable filters should be in the range 18-25 
keV, which is the case for Mo and Rh as shown in Figure 3.  
 
2.2.5 Signal-difference-to-noise ratio (SDNR) 
For SFM contrast is used to rank the image quality, while for FFDM systems the signal-
difference-to-noise ratio (SDNR) is used as figure-of-merit (FOM) for physical image 
quality (93, 94). SDNR quantify the detector behaviour over time and exposure ranges 
using an arbitrary object as proxy, but does not in itself indicate how well a system can 
perform imaging tasks. However, it is a simple measure that can indicate trends. The 
SDNR is used to characterize the quality of the image in terms of potential detectability of 
structures in the breast, such as a calcification or a tumor (92). The SDNR1 is the ratio of 
the signal difference (using the detected rather than the incident number of x-rays): 
ܵܦܴܰ ൌ ௡ಲ೏ି௡ಳ೏ఙ೟೚೟         (8) 
where ݊஺ௗ ൌ ᐭ݊஺ and ݊஻ௗ ൌ ᐭ݊஻are the actual number of x-rays that will be detected for 
paths A and B, which are two different regions of differing signal intensity, respectively, 
and ᐭ is the quantum detection efficiency, which describes the fraction of the x-rays 
incident on the detector that interact with the detector and producing some signal (92, 95). 
The noise variance, ߪ௧௢௧, is the total noise variance for paths A and B. 
 
2.2.6 Detective quantum efficiency (DQE) 
The detective quantum efficiency (DQE) is defined as the degradation in information 
(SNR) caused by the detector relative to the information in the incident beam (91). DQE is 
given by (86): 
ܦܳܧ ൌ ሺௌேோ೚ೠ೟ሻమሺௌேோ೔೙ሻమ         (9) 
 
                                                 
1 The SDNR is a display-independent parameter that can give equivalent information to the contrast-to-noise 
ratio (CNR=Contrast/Noise). The SDNR is a unitless quantity, while CNR has units of inverse noise. CNR 
and SDNR can be shown to be equivalent if the objects being compared are displayed at the same intensity.  
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DQE gives the efficiency of a detector in converting incident x-ray energy into an image 
signal. An ideal detector extracts all the information in the beam (DQE=1), although, a 
partially absorbing detector may be more efficient (provide a higher SNR) than a detector 
that absorbs all the radiation (96).  
 
2.2.7 Modulation transfer function (MTF) 
The DQE and modulation transfer function (MTF) are quantitative measurements of the 
detector performance. MTF is the two-dimensional Fourier-transform amplitude, as a 
function of spatial frequency, of the point spread function (PSF) (97). In short, the MTF is 
the transfer of information at each spatial frequency (86). The MTF has been used to 
characterize the resolution properties of SFM systems (98). However, the MTF’s for 
FFDM systems need to be interpreted carefully due to the aliasing effect, which is caused 
by discrete data sampling. For all real imaging systems there is a loss of spatial-frequency 
information at high spatial frequencies, which is parameterised by the MTF. The MTF, 
DQE and normalized noise power spectrum (NNPS) are used to assess the detector 
performance (91). The DQE can be expressed as (in the 1-dimensional case): 
ܦܳܧሺݑሻ ൌ  ெ்ிమሺ௨ሻ௤బൈ௄ൈேே௉ௌሺ௨ሻ       (10) 
where q0 (ܴܵܰ௜௡ଶ ሻis the integrated x-ray photon spectrum normalized for the air kerma to 
give photons per unit air kerma per mm2 for the x-ray beam (the density of incident x-ray 
quanta), K is the air kerma for the uniformly exposed images and u is the spatial frequency 
variable in cycles per mm (28, 91). The true q0 values depend on the properties of the 
actual x-ray spectrum for a given system, and the q0 values used by Marshall et al. and 
others are therefore only approximate. 
 
2.3 X-ray units dedicated for mammography 
2.3.1 X-ray spectrum 
The spectrum shape is determined by the target material, the applied x-ray tube voltage and 
the added filtration of the beam. Further, the spectrum should be narrow-band in order to 
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attenuate the low-energy x-rays, which only produce high skin doses, and to attenuate the 
high energy photons, which reduce the contrast (88, 99). Image contrast and dose reduction 
improvement in mammographic x-ray imaging can be obtained by using narrow energy 
band x-ray beams in the 16–24 keV range (100).  
 
The x-ray spectrum consists of polyenergetic radiation. An improvement in the diagnostic 
potential of mammography can be achieved by using monochromatic or quasi-
monochromatic x-rays (85). More monochromatic radiation will also result in a reduction 
in the radiation dose. This provides a better contrast of breast lesions and a relevant 
reduction of dose to the patient. The improvement is comparable with the improvement 
expected with scanning slit devices over conventional antiscatter grids. The optimum x-ray 
spectrum is a compromise between image contrast, radiation dose, and the statistical noise 
in the image (101). The main factor that affects the performance of a given x-ray spectra is 
the compressed breast thickness (73, 102, 103). 
 
A combination of bremsstrahlung and characteristic x-ray processes occurs and are used by 
x-ray tubes (85). Characteristic radiation is the radiation emerging when beam electrons 
collide with the inner orbital electrons (K-shell and L-shell). The collision creates orbital 
vacancies which are filled, and this is accompanied by the emission of characteristic 
radiation. The ratio of characteristic to bremsstrahlung intensity is approximately 25% of 
the fluence of the x-ray beam from a molybdenum (Mo) target. The K-edge describes a 
sudden increase in the attenuation coefficient (μ) of photons occurring at photon energies 
just above the binding energy of the K-shell electron of the atoms interacting with the 
photons. The sudden increase in attenuation is due to photoelectric absorption of the 
photons. This is shown as a peak in the curves in Figure 3. The K-absorption edges 
effectively define the upper edges of the “window” of x-ray energies transmitted by these 
filters (88). Energies just below the K-edge filter will to a large extent pass through the 
filter, while x-rays with energies just above the K-edge will to a large extent be attenuated. 
X-rays below the optimum energy band are strongly attenuated, the effect being that both 
the low- and high-energy x-rays are removed to bring their mean-energy nearer to the 
calculated optimum. A partial energy window is created just below the absorption edge 
with an enhanced transmitted spectrum. In a study where a Monte Carlo code and a breast 
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model as proposed by Hammerstein et al. was used it was shown that filters with K-
absorption edges slightly higher than the optimum energy are the most suitable filters, with 
respect to both image quality and dose (67, 104). Such an optimum combination of the K-
edge filter and tube potential produces spectra with a large proportion of photon energies 
that lie within, or close to, the monoenergetic optimum range (88). 
 
Mo anode and Mo filter has been regarded as the “standard” for mammography (99). 
Compared to the tungsten (W) anode, which is commonly used in the majority of 
radiographic procedures, the Mo anode produce softer x-rays (105). The softer x-ray beams 
allow improved visualization of low contrast masses and microcalcifications. Mo emits K-
characteristic x-rays at 17.5 and 19.5 keV in addition to a rich bremsstrahlung spectrum 
between 15 and 20 keV (84, 106) (Figure 3). The target/filter combination Mo/Mo is an 
optimal compromise between low-energy and high-energy spectrum, when operated at a 
tube potential of 24-32 kV (84). For thin to average compressed breast thicknesses the Mo 
characteristic radiation is transmitted through the breast and provides high-contrast 
mammograms (107). For the thick or dense breast the target/filter combinations Mo/Rh 
and Rh/Rh achieved contrast comparable to or better than Mo/Mo at a lower dose (101, 
106). Rh has a higher K-absorption edge (23.2 keV) and higher K-characteristic x-rays 
than Mo, but just like the Mo anode, the Rh anode provide soft x-rays (71, 106, 108). The 
higher K-absorption edge of a Rh filter allows bremsstrahlung of a higher energy (range: 
20-23 keV) (106). At a given kVp the target/filter combination Rh/Rh will be a more 
penetrating beam than in turn a combination of Mo/Rh and Mo/Mo will be (106).  
 
There has been an increase in the use of W anode, especially with full-field digital 
mammography detectors that produce noise-limited images. The shift from Mo to W x-ray 
tube target implies more high-energy photons, the characteristic radiation line spectra for 
W occur at roughly 58 and 69 keV (67-69, 87). W anode provide harder x-rays, seem to 
provide poorer contrast, but do provide lower doses (105). Filters with K-edges above 20 
keV are chosen in order to create relatively narrow band of energies for the W anode (107). 
The target/filter combination W/Rh (Figure 3 c) performs better than Mo/Mo for all 
thicknesses, although the difference is small for the smallest phantom thicknesses (109). 
23 
 
For the thicker breasts, both target/filter combinations tungsten/aluminium (W/Al) and 
tungsten/silver (W/Ag) has shown to provide optimum x-ray spectra (88, 110). 
 
Increasing the filter thickness will increase the percentage of x-rays in the optimum bands, 
making the x-ray beam more penetrating. For the Mo/Mo target/filter combination contrast 
and dose changes little with filter thickness, while the tube loading changes significantly 
with a change in the filter thickness (99). 
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a)  
   
b) 
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c) 
 
Figure 3. Measured absolute (normalized) x-ray spectra at 28 kV a) for the target/filter 
combinations Mo/Mo and Mo/Rh from Siemens Mammomat 3000 and General Electric 
Senographe DMR (the spectra from the two units were inseparable), b) for Mo/Mo and 
Rh/Rh from General Electric Senographe DMR, and c) for Mo/Mo and W/Rh from 
Siemens Mammomat 3000. The x-ray spectrum is presented as the number of photons in 
each photon energy interval (0.1 keV) normalized to the same tube current (mA), total 
exposure time (s) and solid angle (sr). X-ray photon energy distributions were measured 
using a Compton scattering spectrometer. The K-peaks are broadened due to the 
measurement procedure. Figure reproduced from Thilander-Klang et al. (111) with 
permission. The x-ray spectrum is only valid for a given filter thickness. Varying the filter 
thickness will result in a different x-ray spectrum. 
 
 
2.3.2 Half value layer (HVL) 
The half value layer (HVL) is defined as the thickness of high purity Al (≥99.9%) given in 
mm Al which attenuates the air kerma of non-monochromatic x-ray beams by half (29). 
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HVL is used to describe the radiation quality (target, filter, kV and the output from the 
generator). An increase in HVL results in a lower radiation dose (101), and a lower image 
contrast (69). The HVL can be assessed by adding thin Al filters to the x-ray beam and 
measuring the attenuation for all target/filter/kV combinations in use for a given 
mammography unit (29). 
 
For 28 kV Mo/Mo the HVL must be over 0.30 mm Al equivalent, and is typically <0.40 
mm Al (112). The HVL varies for different target/filter combinations and choice of tube 
output (kV) (Table 1). 
 
 
Table 1. Typical values for the HVL (mm Al) for different choices of target/filter 
combination and choice of tube output (kV). The data are from Table A5.3 in the 
“European protocol for the quality control of the physical and technical aspects of 
mammography screening” and Table A5.3 in “Supplement to the European Guidelines” 
(112, 113). The HVL is measured for tube outputs in the range 25-37 kV. 
Target/filter combination HVL range (mm Al) 
Mo/30 μm Mo 0.32㼼0.02-0.40㼼0.02 
Mo/25 μm Rh 0.38㼼0.02-0.47㼼0.02 
Rh/25 μm Rh 0.37㼼0.02-0.47㼼0.02 
W/50 μm Rh 0.50㼼0.03-0.62㼼0.03 
W/0.45 μm Ag 0.51㼼0.03-0.67㼼0.03 
W/0.5 mm Al 0.34㼼0.03-0.53㼼0.03 
W/ 0.7 mm Al 0.50㼼0.03-0.62㼼0.03 
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2.3.3 Anti-scatter grids  
In mammography the x-rays may pass through the breast without interaction, be absorbed 
or scatter in the breast and escape (7). The x-rays that pass through the breast without 
interacting, versus the x-rays which are absorbed, are carriers of diagnostic information 
and form the image. Incoherent or coherent scatter on the other hand will just blur the 
image. In mammography low energies are used, but still x-rays scattered in the breast and 
recorded by the image receptor contribute greatly to degrade the contrast in the image (7, 
84). The amount of scattered radiation towards the imaging system for an average breast 
may amount to as much as 70% of the number of directly transmitted x-rays (7, 114).  
 
The traditional way of rejecting scattered radiation is by placing a grid between the breast 
and the detector. In order to avoid the presence of grid lines in the image, the grid has to 
move during the exposure. Mammography anti-scatter grids transmit 60-75% of the 
primary x-rays, and absorb 75-85% of the scattered radiation (115-118). By reducing the 
scatter-to-primary ratio the radiation dose has to increase in order to maintain the same 
amount of primary photons for SFM, which are the carriers of diagnostic information, as 
without a grid. The factor (Bucky factor) by which the tube current (mAs) must be 
increased for SFM is in the order of 2.5-3 (84). Due to a larger dynamic range for FFDM 
systems the reduced exposure to the detector due to the grid does not necessarily imply an 
increase in dose (94). 
 
The shortcomings of anti-scatter grids are that a large fraction (15-25%) of the primary 
radiation is absorbed by the grid, and that scattered radiation can still traverse the grid (25-
40%). All systems used for mammography in the NBCSP have anti-scatter grids, with the 
exception of multislit scanning digital systems, due to their high efficiency in rejecting 
scattered radiation (94). 
 
2.3.4 Automatic exposure control (AEC) 
The AEC is an x-ray exposure termination device, and consists of a sensor located beyond 
the image detector. When the sensor has received a predetermined amount of radiation the 
exposure discontinues. The ALARA principle on dose administered to the patient urges the 
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use of an AEC system to ensure the optimal exposure of the image receptor compensating 
for breast thickness and composition (119). 
 
For the SFM systems included in Paper I from General Electric (GE), Instrumentarium2 
and Siemens different approaches to automation of exposures are employed. Siemens and 
Instrumentarium determine the exposure values based on compressed breast thickness. For 
GE the detector is used as the AEC sensor, as detector operation entails separate 
acquisition and image-read phases (44, 120), and a short pre-exposure is given in order to 
find the correct choice of target/filter/kVp/mAs. In Paper I-V FFDM systems from GE, 
Siemens, Hologic and Philips were included. The FFDM systems from GE and Siemens 
have similar AEC set-up as the SFM systems. Hologic has a similar AEC as GE, basing 
exposure on registered breast thickness and signal recorded during a brief pre-exposure 
(121). Philips on the other hand permits instantaneous AEC sensor operation during image 
acquisition using the leading edge detector (122). 
 
2.3.5 Compression 
Compression is important in mammography, and should be applied slowly and gently 
(123-125). It serves several purposes: a) spreading out the tissue and thereby reducing 
superposition, b) reducing the scatter-to-primary ratio (126), c) reducing the dose since a 
thinner breast is more easily penetrated, d) causing less image blurring and reducing the 
degree of geometric magnification, since all parts of the breast will be closer to the 
imaging system (84), e) decreasing the breast thickness, and f) resulting in improved breast 
contrast, due to decreasing relative intensity of scatter and a reduction of beam hardening 
(126).  
 
Flat paddles with an abrupt 90-degree flange at the chest wall are widely used now, since 
these paddles grip the posterior breast and achieve more uniform compression compared to 
curved paddles (126). It has been revealed that variability between and within practitioners 
do exist (127), and that compression plates have an unsuitable pressure distribution (128, 
129).  
                                                 
2 Now owned by GE. 
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2.3.6 Screen film mammography (SFM) 
Mammographic images are produced with a single intensifying screen used as a back 
screen in combination with a single-emulsion film (130). The mammographic screens 
incorporate phosphors containing metals from the lanthanaide series, and may incorporate 
light absorbed in the phosphor in order to increase sharpness. All radiologic images contain 
random fluctuation, or noise, due to the statistics of x-ray quantum absorption (131). Film 
granularity is a major noise source (132).  
 
In the NBCSP the two screen film combinations Kodak Min-R 2190/Kodak Min-R 2000 
and Kodak Min-R EV 190/Kodak Min-R EV were in use in the time period 2006-2008. 
The characteristic curve of the screen film system Kodak Min-R EV 190/Kodak Min-R EV 
provides the highest contrast over the widest optical density (OD) range compared to 
Kodak Min-R 2190/Kodak Min-R 2000 (Figure 4). The Kodak Min-R EV 190/Kodak 
Min-R EV screen film combination is the newest of the two and has a) a comparable 
sensitivity, b) a better contrast, c) a higher MTF, d) slightly better resolution, and e) an 
equivalent noise level to Kodak Min-R 2190/Kodak Min-R 2000, although the Kodak Min-
R 2000 film is the noisiest film (133, 134). For the Kodak Min-R EV system the glandular 
part of the breast should be imaged at a higher OD than usual (for example: 1.0–1.2), 
requiring the AEC system to be set to a higher range, i.e. 1.8–2.0 instead of 1.4–1.6. This 
shift in OD would increase the entrance dose compared to the screen film combination 
Kodak Min-R 2190/Kodak Min-R 2000.  
 
Radiographic film is limited by the fact that the gradient of the characteristic curve varies 
with exposure level. Successive doubling of the exposure does not give a constant increase 
in the density, i.e. the opacity is not proportional to the exposure. The central region of the 
characteristic curve is called the "linear" or "straight-line" portion, the underexposed part is 
called the "toe", and the overexposed region is called the "shoulder". In mammography the 
AEC has a very important role when it comes to improving the consistency of film OD, 
contrast and radiation exposure (118). 
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Figure 4. The characteristic curve, which is a plot of film density (log of opacity) versus 
the log of exposure, for the screen film combinations Kodak Min-R 2190/Kodak Min-R 
2000 and Kodak Min-R EV 190/Kodak Min-R EV. The sensitometer had a maximum 
reading of approximately 4.5 for the optical density (OD). 
 
 
2.3.7 Full-field digital mammography (FFDM) 
The processes of image acquisition, image display, and storage are separated in digital 
mammography, in contrast to SFM. This allows for optimization of each of these processes 
separately (120). The FFDM systems included in Paper I-V utilizes different kinds of 
digital technology: a) selenium flat-panel digital detector, b) flat-panel phosphor digital 
detector, c) and photon counting scanning-slit detector (135). a) and c) are so-called direct 
and b) is an indirect systems, respectively (Figure 5).  
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Figure 5. Signal conversion principle for direct and indirect detectors. Figure reproduced 
from Noel and Thibault (136) with permission. 
 
 
Selenium flat-panel digital detector is a direct conversion detector; the x-ray energy is 
converted directly into electric charge using a photoconductive detector. The x-rays 
interact with an amorphous selenium (a-Se) photoconducting layer and an electric charge is 
liberated in the material in the form of electron-hole pairs. Electrodes are placed on the 
upper and lower surfaces of the selenium, and an electric field is applied between the 
electrodes. The electric charge is collected by a matrix of electrodes. The advantages of 
this system are a) a high DQE and b) a high MTF (137). Measurements for the DQE and 
MTF published by Marshall et al. showed that the peak DQE for GE Senographe 2000D, 
GE Senographe DS, GE Essential, Hologic Selenia, Sectra MDM (in the scan direction), 
and Siemens Inspiration were 0.41, 0.40, 0.59, 0.48, 0.81, and 0.44, respectively, while the 
MTF at 5 mm-1 were 0.27, 0.28, 0.16, 0.44, 0.22 and 0.48, respectively (91). The MTF for 
the newer GE Essential detector is lower than for the older generation detectors GE 
Senographe 2000D and GE Senographe DS. Siemens Inspiration and Hologic Selenia both 
have a-Se based detectors, and for these the difference in MTF was small (0.44 versus 
0.48). 
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Flat-panel phosphor digital detector is called indirect-conversion detector; the x-ray energy 
is first converted to light by an x-ray scintillator (cesium iodide is a common scintillator), 
which in turn is converted to an electric signal. The electric signal is transferred to be 
stored as a charge on the large-area detector. An advantage of phosphor flat-panel systems 
is that the images can be obtained in a short period of time (138). The pixel size of the 
detector elements of the phosphor flat-panel systems is 100 μm, the selenium-based 
systems has a pixel size of 70-85 μm and the pixel size of the photon counting scanning-
slit detector from Philips is 50 μm.  
 
A special type of a direct detection radiography system is the individual counting of each 
interacting x-ray photon (119). One photon produces exactly one count regardless of its 
energy. The detector is a multi-slit scanning system that uses an array of silicon wafers to 
detect the x-rays (94, 139). This way the electronic noise is reduced, and by utilising a high 
energy spectrum and not applying a standard grid design this reduces the patient dose by 
55-65% (135, 140, 141). While the flat-panel systems operate with sophisticated systems 
for automatic optimization of the radiation parameters, the scanning system determines 
exposure based only on the breast thickness (119). 
 
2.3.8 Technological development: Transition from 
screen film mammography (SFM) to full-field digital 
mammography (FFDM) 
SFM has remained in use for a long time, and was close to being fully optimized when 
FFDM first came into use (142). The reason why SFM has been in use for such a long 
time, even though FFDM has been available is a) the concern of a lower spatial resolution 
in digital systems, b) concern about using soft-copy reading (143), and c) the cost, FFDM 
being more expensive than SFM (144, 145). However, since all other modalities in the 
radiology departments (x-ray, computed tomography (CT), magnetic resonance imaging 
(MRI) and ultrasound) were developing towards digital equipment and picture archiving 
and communication system (PACS), mammography was pushed in the same direction 
(119, 142), which improved the information flow in the hospitals. From the 1990s onward, 
digital mammography has become increasingly available (146), and is gradually replacing 
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SFM (147, 148). The main difference between SFM and FFDM is the separation of the 
image acquisition, processing and display (142).  
 
The advantages of SFM are: a) low cost, FFDM costs 1.5-4 times more (149), and b) SFM 
is superior to FFDM when it comes to spatial resolution (142). An important limitation 
with SFM, however, is the contrast resolution (142). The limitations of SFM are partly due 
to the detector, and to the image acquisition geometry (inefficiency of scatter rejection) 
(131). The SFM detector has: a) shorter dynamic range (the range of light intensities that 
can be captured simultaneously) (Figure 6), b) restricted exposure latitude (the extent to 
which a light-sensitive material can be overexposed or underexposed and still achieve an 
acceptable result), c) restricted contrast, d) lack of detection efficiency, and e) presence of 
film-granularity noise.  
 
Many of the limitations of conventional mammography could be effectively overcome 
with a FFDM imaging system in which image acquisition, display, and storage are 
performed independently, allowing optimization of each of them separately (131). The 
advantages with FFDM are among others: a) a wider dynamic range, b) linear relationship 
between dose and signal intensity, c) higher cancer detection rate, d) dose savings for 
women with larger breasts, and e) the possibility of image processing (142, 143, 150). The 
wider dynamic range gives FFDM a clear advantage over SFM. With SFM parts of an 
image might be under- or overexposed, but this is avoided with FFDM. Further, for SFM 
the limited dynamic range results in difficulty in detecting soft-tissue lesions in dense 
glandular tissue (142). A higher cancer detection rate for FFDM is obtained in younger 
women with denser breasts due to FFDMs ability to selectively optimize contrast in areas 
of dense parenchyma (138). Dose savings for women with larger breasts is obtained by 
switching to a higher energy beam spectrum (151, 152). The image may be processed after 
the image is obtained by changing the dynamic range of the breast tissue. 
 
Early dose studies for FFDM showed a reduction in glandular dose of 25-35%, depending 
on breast thickness (119, 138, 151). Studies comparing radiation doses from one FFDM 
with one or more SFM systems have found that FFDM systems are capable of providing 
lower radiation doses than SFM systems (151, 153-155).  
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Figure 6. The dynamic ranges for screen-film systems and digital detectors. Screen film 
systems have a limited tolerance for radiation exposure, while digital detectors cover a 
wider range. Therefore, an optimal signal response will occur over a wider exposure range 
with digital detectors than with screen film systems. Figure reproduced from Korner (156) 
with permission. 
 
 
In the diagnosis of microcalcifications, FFDM is equivalent or superior to SFM (143, 157-
163). GE’s Senographe 2000D was used in most of these studies, although other systems 
(FFDM: Fischer, Lorad, Hologic and Sectra; CR technology) were represented as well 
(143). Objects with size smaller than the pixel size of a digital detector will be displayed as 
a) larger than they actually are and b) with a lower contrast (138, 159, 164). This could be 
a worry in the detection and characterization of microcalcifications, but seems to be 
irrelevant. The lower spatial resolution of FFDMs is more than compensated for by other 
characteristics leading to an enhanced detection of microcalcifications (119). 
 
When it comes to the detection and characterization of masses, FFDM seems to perform at 
least equivalent to SFM (119). However, when it comes to detecting cancer, FFDM is 
superior to SFM only in younger women (<50 years) (165). Although, as long as only 
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women aged 50-69 years is screened in the NBCSP, this last finding is not of importance 
as of now for the women invited in the NBCSP. Digital systems have higher DQE, and 
therefore lower noise. Due to this, digital systems can compensate for the relative loss of 
contrast via appropriate windows settings.  
 
Overall, studies conducted on different FFDM systems (Fischer (SenoScan), Fuji (CR 
system), GE (Senographe DS and Senographe 2000D), and Hologic (a digital 
mammography system and Lorad Selenia)) have shown that FFDM is just as accurate as 
SFM (144, 149, 166). However, one disadvantage was found for FFDM in that recall rates 
were higher compared to SFM (166).  
 
2.4 Radiological protection and risk of 
radiation-induced cancer 
Ionizing radiation is defined as radiation that has sufficient energy to remove orbital 
electrons from an atom or molecule (87). In the human body, ionizing radiation can be 
absorbed and damage DNA (167). The mechanism of DNA damage can be either direct or 
indirect. Direct damage comes from an ejected electron, and indirect damage through the 
production of free radicals, such as hydroxyl radicals from water. The hydroxyl radicals 
can then go on to damage DNA. The indirect effect is the predominant effect from x-rays. 
 
2.4.1 Definition of risk: Absolute and relative risk 
After the discovery of x-rays, it was revealed that radiation exposure causes acute tissue 
damage and cancer, particularly leukemia (168). The health effects consequent to exposure 
to ionizing radiation are divided into two categories: a) tissue reactions (previously referred 
to as ‘deterministic effects’) and b) stochastic effects (62). Acute skin reactions in the most 
heavily radiated area are a major concern for patient safety especially in interventional 
radiology (56). Dose responses for radiation-induced tissue reactions in adults and children 
seem to have dose thresholds, which result in the absence of risk at low doses (62). 
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Stochastic effects consist of cancer in the exposed individual and hereditary disease in the 
descendants of the exposed individual. Cancer induction is generally considered to 
dominate the overall risk for the exposed person after radiological imaging (56). The 
stochastic nature of radiation carcinogenesis is the basis for the ALARA principle (169).  
 
Epidemiological studies conducted in the past 6 decades have attempted to document the 
health consequences of exposure to low levels of ionizing radiation (170). There are four 
categories of data sources: a) atomic bomb survivors in Hiroshima and Nagasaki 
(Radiation Effects Research Foundation (RERF) data, Japan), b) persons exposed to 
medical radiation, c) workers in radiation and nuclear industries, and d) populations 
exposed to environmental radiation (including accidents in nuclear plants). The Japanese 
atomic bomb survivor life span study (LSS) cohort data, which is an ongoing study, is the 
major source when it comes to evaluating health consequences from ionizing radiation (62, 
171, 172). The latest report in a series of periodic general reports on mortality in the LSS 
cohort of atomic bomb survivors concludes that the risk of all causes of death was 
positively associated with radiation dose (173). Most of the other population studies have 
shown no or much smaller health effects due to radiation exposure than the RERF data 
(171).  
 
For the RERF data extrapolations are difficult due to differences in cancer incidence 
between the population of Japan and other populations and differences in exposure from an 
atomic bomb and medical imaging.  
 
Risk is defined as the probability for an individual to develop a specified disease over a 
specified interval of time. It is assumed that the individual is alive and disease-free at the 
start of the time period. There are two essential components of risk assessment: a) measure 
of exposure (absorbed dose from ionizing radiation) and b) measure of disease occurrence. 
Evaluation of the association between exposure and disease occurrence is aided by the use 
of statistical models.  
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Absolute risk is defined as the probability that a person who is disease-free at a specific 
age will develop the disease at a later time in life following exposure to a risk factor. For 
example: the probability of cancer induction following exposure to radiation. In the excess 
absolute risk (EAR) model ionizing radiation is assumed to induce cancers at some fixed 
number above the natural incidence, and it is defined as (170): 
ܧܣܴ ൌ ܴ௘ െ ܴ௨        (11) 
where ܴ௘ are the incidence rates in an exposed population and ܴ௨ are the rates in an 
unexposed population. The EAR is expressed per population and time period (e.g. per 
10 000 person-years). The excess relative risk (ERR) is expressed as a fraction or multiple 
of the naturally occurring risk: 
ܧܴܴ ൌ ோ೐ோೠ െ ͳ         (12) 
ܴ௨ is often referred to as the baseline risk. The ERR is the excess risk expressed relative to 
the background risk. The ERR model assumes that exposure to ionizing radiation increases 
the natural incidence of a cancer at all ages proportional to spontaneous background rates 
(predicts a larger number of induced cancers in old age). This value is always greater than 
1 (unless the radiation is assumed to produce a beneficial effect). The risk in the exposed 
population may be expressed as:  
ܴ݅ݏ݇݅݊݁ݔ݌݋ݏ݁݀ ൌ ܤܽݏ݈݁݅݊݁ݎ݅ݏ݇ ൅ ܧܣܴ    (13) 
ܴ݅ݏ݇݅݊݁ݔ݌݋ݏ݁݀ ൌ ܤܽݏ݈݁݅݊݁ݎ݅ݏ݇ሺͳ ൅ ܧܴܴሻ   (14) 
Risk factors from the EAR and ERR models are incorporated into a final risk model, the 
lifetime attributable risk (LAR) model to compute a risk estimate for the likelihood of 
radiation-induced cancer over the lifetime of individuals exposed to ionizing radiation. 
This approach is applied by United Nations Scientific Committee on the Effects of Atomic 
Radiation (UNSCEAR), in the report of the 7th committee of the Biologic Effects of 
Ionizing Radiation (BEIR VII) commissioned by the U. S. National Academy of Sciences, 
and by ICRP for estimating the likelihood of radiation-induced cancer (62, 171, 174). 
UNSCEAR has converted ERR into LAR in a way that differs from the ICRP procedure 
(175).  
 
The radiogenic risk varies with the different x-ray procedures and to differing degrees 
depending on which body organ that has been irradiated (176). Further, it varies 
38 
 
significantly with the patient`s age and sex. In children the risks of radiation-induced 
stochastic health effects are estimated to be higher (by a factor of ≤4) than in adults, while 
for people ≥70 years the risks are lower (by a factor of ≥10) compared to younger people 
(176). Within the LSS, the ERR decreases with increasing age at exposure, while the EAR 
does not (174). 
 
2.4.2 The dose-response relationship 
Epidemiology is the study of the distribution and determinants of disease in human 
populations, and the relationship between an outcome (disease) and an exposure is studied 
(dose-response relationship).  
 
For doses above 100 mGy the relationship between radiation dose and radiation related 
cancer risk is found to be linear (170, 177-185). Further, there is consensus that for doses 
in the range 0.2 to 3 Gy the so called linear no-threshold (LNT) dose-response model 
describes well the relation between the radiation dose and carcinogenic effect (186). The 
LNT model predicts that the excess risk of cancer is directly proportional to the dose of 
radiation received.  
 
Radiation risk at low doses (<100 mSv) is commonly extrapolated from the risk at high 
doses (187-189). Different extrapolations can be conducted: a) linear extrapolation (LNT), 
b) linear quadratic model, c) threshold linear model, and d) hormesis model (Figure 7) 
(190). In the threshold model very small radiation doses are considered to be harmless. The 
hormetic model argues that radiation at very small doses can even be beneficial. For the 
LNT model it is considered that the sum of several very small exposures have the same 
effect as one larger exposure and the implication is that no dose of radiation is safe. For 
low doses, however, the risk is too small to be distinguishable from cancer incidence due 
to all causes, and an increased incidence of cancer has been difficult to identify with any 
degree of statistical confidence (168, 170, 187).  
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Figure 7. Different models (dashed straight lines) for extrapolating from the LNT model 
(straight line) applied at high doses (>100 mSv) to low: a) supra-linearity (downward 
curving curve) b) linear extrapolation (LNT), c) linear no-threshold model, and d) hormesis 
model. The linear-quadratic model would be between the linear no-threshold model and 
the hormesis model, with an upward curving curve and no positive effect at low doses. 
Figure reproduced from Hendee and O’Connor (170) with permission.  
 
 
Assuming a hypothetical dose-response curve with a linear approximation for low doses 
(the tangent of the curve at dose zero, with slope sL), and a linear approximation based on 
risk at some high dose (with slope sH), the dose and dose-rate effectiveness factor 
(DDREF) is the slope at high dose (sH) divided by the slope at the smaller dose (sL) (171). 
If the DDREF is known, it can be used to convert a risk estimate (EAR) from the high dose 
(EARH) to the low dose (EARL) (171):  
ܧܣܴ௅ ൌ ா஺ோಹ஽஽ோாி         (15) 
The ICRP uphold the recommendation of applying a DDREF of 2 to correct for a lower 
effect at low doses and low dose-rate, while BEIR VII use a DDREF of 1.5, and 
UNSCEAR use a DDREF of 1 (62, 171, 191). 
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The LNT model is first and foremost used due to its simplicity and conservative approach 
(170, 192). When estimating the radiation risk, an LNT model is normally assumed, 
although the application of the LNT model at low doses, such as for mammography, is 
heavily debated (170, 189, 192, 193). Expert advisory bodies are divided in their view of 
the LNT model (194). One of the reasons being that the LNT theory fails to differentiate 
between low doses delivered at low dose-rates, high doses delivered at high dose-rates, and 
the effects of these. BEIR VII and ICRP support the hypothesis of the LNT relationship 
between exposure to ionizing radiation and the development of cancer in humans at low 
doses (171, 195). The French National Academies of Science and Medicine on the other 
hand concluded that the LNT model lacks justification for low doses (<100 mGy), and 
even more for very low doses (<10 mGy) (186). Either, because there is no effect, or the 
effect is too small to be detected by such studies. They base this decision partly on 
radiobiological evidence from epidemiological studies (194). They argue that the LNT 
model is not based on scientific data, and that the LNT model should only be used as a tool 
for regulatory purposes (186).  
 
From a radiation protection point of view a conservative model that overestimates risk is 
preferred over a model that underestimates risk. The ICRP maintains that it is better to err 
on the side of caution (62). The LNT theory lays the foundation for current radiation 
protection philosophy (194). However, the LNT model was originally used to provide an 
upper limit estimate of the risk, with zero being the lower limit, of low level irradiation, 
since the dose-response curve could not be determined at low dose levels (196). The 
evidence supporting linearity for radiation was limited and not based on low doses (197). 
For low doses, in general, there are large statistical fluctuations (62, 190). For instance, no 
statistically significant increase in cancer risk was found in two areas with high 
background radiation (198, 199). In order to obtain statistical precision, the sample size 
must increase approximately as the inverse square of the dose (187); a sample size of 
approximately 5 million people would have to be included for a 10 mGy dose (200, 201). 
In 2007 the ICRP stated that “the long standing question on the true validity of the LNT 
model may well prove to be beyond definitive scientific resolution and that “weight of 
evidence” arguments and practical judgments are likely to continue to apply in the 
foreseeable future” (62). 
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2.4.3 Radiation effects on the female breast 
Radiation exposure of the female breast from mammography from 1960 to the present 
shows that glandular tissue doses have decreased from an average of about 12 mGy to 
about 2 mGy (146). In the NBCSP dose surveys have been conducted by the NRPA since 
the start of the trial project (40, 202, 203). In the dose surveys the conversion factors of 
Klein et al., Wu et al. and a revised model of Dance et al. were applied when estimating the 
MGD (41, 42, 66, 71, 76). The MGD for the CC and MLO projections were no higher than 
1.5 mGy (range: 1.17-1.38 mGy), while the MGD per examination was in the range 2.5-3.0 
mGy. 
 
Radiation effects on female breast cancer rates have been widely studied (181, 182, 204-
210). The reason for this is that breast tissue appears to be relatively radiosensitive and 
because breast cancer is the most common cancer among women (174).  
 
The atomic bomb survivor cohort (LSS) consists of a population that was primarily 
exposed to high energy, low (<1 keV μm-1) linear energy transfer (LET) gamma radiation, 
while mammography x-rays are low energy exposures (photon energies about 30 keV) 
with higher LET (>1 keV μm-1) compared to gamma rays (211, 212). The relative 
biological effectiveness (RBE), which is the ratio of biological effectiveness of one type of 
ionizing radiation relative to another, given the same amount of absorbed energy, is lower 
for x-rays, gamma rays, beta rays, and muons than for neutrons, protons, charged pions, 
alpha particles, nuclear fission products, and heavy nuclei. RBE is represented in 
regulations by the radiation weighting factor. Thus, the difference in RBE makes it 
difficult to compare the atomic bomb victims and exposures from medical imaging. In 
vitro studies on double-strand breaks (DSB) have shown that more clustered DNA damage 
is produced with mammography x-rays compared to gamma rays (211). These are more 
difficult to repair. Further, a RBE (for malignant transformation of human cells in vitro) of 
4 for mammographic x-ray energies relative to higher energy x-rays has been found (212-
214). If an RBE of 4.0 is assumed for mammography x-rays, there is no impact on the 
detection to induction ratio for women aged 50-70 years, and thus mammography still 
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remains a low risk procedure (212). There exists controversy regarding the RBE of low 
energy x-rays applied for mammography (212, 214, 215). 
 
In the LSS an EAR per 104 woman-years per Gy of 2.3 (95% CI: 1.0-3.8) was found for 
breast cancer (173). The EAR was estimated for women exposed at age 30 years, having 
attained age 70 years. For Canadian tuberculosis patients given chest fluoroscopies the data 
were most consistent with a linear dose-response relationship, and this was confirmed in a 
follow-up study as well (209, 216). They found a standardized mortality ratio of 1.14 (95% 
CI: 1.02-1.27) for women exposed to a cumulative dose <100 mGy, which they defined as 
the unexposed group. Women exposed to a cumulative dose ≥100 mGy of radiation had a 
relative risk of death from breast cancer compared to the unexposed group of 1.36 (95% 
CI: 1.11-1.67) (216). However, it was concluded that the risk of breast cancer associated 
with radiation decreases sharply with increasing age at exposure. Further, it was concluded 
that even a small benefit to women of screening mammography would outweigh any 
possible risk of radiation-induced breast cancer. Overall, the studies seem to show a linear 
correlation, although age and radiation dose included in the studies are not the same as 
those that are applied in the NBCSP. 
 
2.4.4 The principles of the International Commission 
on Radiological Protection (ICRP) 
Modern radiological protection is based on the three principles of the ICRP, which were 
published in Publication 26 in 1977 (39): 
x Principle of justification: no practice involving exposure to ionizing radiation shall 
be adopted unless it produces a net benefit.  
x Principle of optimization: all exposures shall be as low as reasonably achievable, 
economic and social factors taken into account. 
x Principle of limitation: exposure of radiation workers and members of the public 
must not exceed dose limits. 
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Their practical implementation requires procedures and methods for the quantification of 
exposures to ionizing radiation (217). In a screening setting and from a radiation protection 
point of view the radiation doses have to follow the ALARA principle (170).  
  
44 
 
  
45 
 
 
3 Aims of the individual 
papers 
Paper I 
With FFDM units it is anticipated that the dose level will decrease compared to using SFM 
units. In the time period 2006-2008 a gradual shift from SFM to FFDM was taking place in 
the NBCSP, and a dose survey was conducted in order to evaluate the MGD for the 
screening units operating in the NBCSP.  
 
Paper II 
The estimation of MGD is based on the compressed breast thickness. Previous studies have 
shown that the readout3 thickness of mammography machines is inaccurate, and some of 
these studies have proposed methods which may provide a better estimate of the 
compressed breast thickness (218-222). Some of the methods are quite accurate, although 
cumbersome to perform (221, 222). We therefore wanted to come up with an easy method 
to measure the difference between the displayed and real (measured) compressed breast 
thickness. Further, we wanted to estimate the difference between displayed and real 
(measured) compressed breast thickness for a range of SFM and FFDM units in clinical 
use. 
 
Paper III 
The uncertainty due to difference between the displayed and real (measured) compressed 
breast thickness will lead to uncertainties in the estimated MGD. The aim in this paper was 
to compare the uncertainties in compressed breast thickness with uncertainties in other 
parameters, such as HVL, glandularity, kerma, and s-factor, in order to estimate the total 
uncertainty in MGD. 
 
                                                 
3 Displayed by the mammography machine 
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Paper IV 
Given that a complete transition from SFM to FFDM had taken place by August 2010, it 
was needed to establish a new DRL in the NBCSP, since FFDM in general provide lower 
MGDs than SFM (Paper I). We wanted to estimate both the 75th and 95th percentile for the 
different manufacture/models. Further, we wanted to investigate if potential differences in 
MGDs for the different manufacture/models could be explained by variations in image 
quality (SDNR and low contrast detectability). And if this was the case, would it then 
render the use of different DRLs for the different manufacture/models. 
 
Paper V 
The aim was to estimate the risk of radiation-induced breast cancers for the women in the 
NBCSP, which offers women aged 50-69 years two-view mammography every two year. 
Yaffe and Mainprize described a scheme for estimating the risk of radiation-induced breast 
cancers, breast cancer deaths, the number of lives lost, and lives saved for a variety of 
mammography screening scenarios (223). However, biennial screening for the age group 
50-69 years, as recommended by the European guidelines for breast cancer screening and 
diagnosis, was not included in their estimates. We wanted to apply the scheme developed 
by Yaffe and Mainprize to estimate the risk for the age range of the women that are invited 
in the NBCSP. 
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4 Material and methods 
4.1 Material: Mammography units 
For Paper II units in use clinically in Lancashire, Greater Manchester and Cheshire 
counties in England, United Kingdom (UK), in 2010 were included. 
 
For Paper I, III, IV and V mammography units used for screening in the time period 2006-
2011 in the NBCSP were included. For the trial project, which started up in 1995/1996, 
four SFM units were used (three Siemens Mammomat 300 and one were used Siemens 
Mammomat 3000) (40). The NBCSP was gradually expanded, and more SFM units were 
added to the program. In year 2000, the first FFDM unit was taken into use in the NBCSP, 
a GE Senographe 2000D unit. Since then there has been a gradual increase in the number 
of FFDM units used for screening in the NBCSP (Figure 8). Since August 2011 only 
FFDM units are used for screening in the NBCSP. Available target/filter combination(s) 
for the different SFM and FFDM units included in Papers I-V are shown in Table 2 and 
Table 3, respectively. 
 
The SFM units included in the study in Paper I were manufactured by GE (GE Medical 
Systems, Buc, France), Instrumentarium and Siemens (Siemens Healthcare, Erlangen, 
Germany). All SFM units had screen film detector systems delivered by Kodak (Rochester, 
NY, USA)4. The FFDM units included in the studies in Paper I-V were manufactured by 
GE, Hologic (Hologic Inc., Bedford, MA, USA), Philips (Philips healthcare, Best, The 
Netherlands) and Siemens.  
 
                                                 
4 Kodak has changed name to Carestream Health Inc. (Rochester, NY, USA). 
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Figure 8. Screen film mammography (SFM) systems and full-field digital mammography 
(FFDM) systems used for screening in the Norwegian Breast Cancer Screening Program 
(NBCSP) since the beginning of the program in 1995/1996. The distribution between SFM 
and FFDM is given in percent (%). 
 
 
Table 2. Available target/filter combination(s) for the different screen film mammography 
(SFM) units included in Paper I, II and IV. 
Manufacturer Model Available target/filter 
combination(s) 
GE Senographe 800T Mo/Mo, Mo/Rh 
GE Senographe DMR Mo/Mo, Mo/Rh, Rh/Rh 
Instrumentarium1 Alpha Mo/Mo, Mo/Rh 
Instrumentarium1 Diamond Mo/Mo, Mo/Rh 
Siemens Mammomat 300 Mo/Mo 
Siemens Mammomat 3000/3000Nova Mo/Mo, Mo/Rh, W/Rh 
1: Now owned by GE. 
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Table 3. The available target/filter combination(s) used for the different full-field digital 
mammography (FFDM) units included in Papers I-V. 
Manufacturer Model Available target/filter 
combination(s) 
GE Senographe 2000D Mo/Mo, Mo/Rh, Rh/Rh 
GE Senographe DS Mo/Mo, Mo/Rh, Rh/Rh 
GE Senographe Essential Mo/Mo, Mo/Rh, Rh/Rh 
Hologic  Lorad Selenia Mo/Mo, Mo/Rh, W/Rh1, W/Ag1 
Hologic  Selenia Dimensions W/Rh, W/Ag2 
Philips3 MicroDose Mammography D40 W/Al 
Philips3 MicroDose Mammography L30 W/Al 
Siemens Mammomat Novation DR Mo/Mo4, Mo/Rh4, W/Rh 
Siemens Mammomat Inspiration Mo/Mo4, Mo/Rh4, W/Rh 
1: For the study published in Paper I the target/filter combinations Mo/Mo and Mo/Rh were applied, while for the study 
published in Paper IV the Mo anode had been replaced by a W anode and the target/filter combinations W/Rh and W/Ag 
were used. 
2: In the user manual for Hologic Selenia Dimensions the target/filter combination W/Al is also listed, although this 
combination was not applied in this study. 
3: The scanning multislit system was developed by Sectra. Royal Philips Electronics (Best, The Netherlands) bought 
Sectra’s (Linköping, Sweden) mammography-modality operations worldwide (except for New Zealand and Australia), 
and took over the modality operation September 1, 2011. 
4: Only the target/filter combination W/Rh was used. 
 
 
4.2 Material: Patient population 
All women aged 50-69 years are invited to biennial screening in the NBCSP. The women 
included in Paper I, III and IV were chosen at random. The women are invited by a 
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personal letter to have a two view (CC and MLO) mammographic screening biennially 
(Figure 9).  
 
 
a)                                                               b) 
 
 
 
 
 
 
Figure 9. Two view screening examination in the Norwegian Breast Cancer Screening 
Program (NBCSP) is generally made up of one a) CC and one b) MLO of the left and right 
breast, respectively. Pictures: courtesy of Oslo University Hospital. 
 
 
4.3 Method: Estimation of the mean 
glandular dose (MGD) in the NBCSP 
The MGD is normally estimated per projection (craniocaudal (CC) and mediolateral 
oblique (MLO)), and per examination, where one examination consists of one projection of 
each breast. 
 
When estimating the MGD in this papers that are part of this thesis, the method and 
conversion factors used proposed by Dance et al. have been applied (41, 42, 70). 
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The incident air kerma, ܭ௔ǡ௜, was measured with a Radcal Ion Chamber Model 10x5-6M 
connected to a Radcal Electrometer/Ionchamber Model 9060 and Radcal Radiation 
Monitor Controller Model 9010 (Radcal Corporation, Monrovia, CA, USA) (Figure 10). 
Radcal Ion Chamber Model 10x5-6M is a dedicated mammography chamber. Calibration 
was conducted in 2008, 2010 and 2012. Until 2008 the Radcal ionization chamber was 
calibrated at the Radiological Protection Centre (RPC) (location: London, UK), but since 
2010 it has been calibrated at the Secondary Standard Dosimetry Laboratory (SSDL) at the 
NRPA (location: Østerås, Norway). The calibration factors from the calibration certificate 
are applied when estimating the air kerma.  
 
The incident air kerma, ܭ௔ǡ௜, was measured for all applied target/filter and tube voltages for 
each mammography screening unit. When conducting the measurements, the ionization 
chamber was positioned 45 mm above the breast support table on a line extending from the 
tube focus to a point on the mid-line of the breast support table, 6 cm from the chest wall 
edge, and in contact with and below the compression paddle. The inverse square law was 
applied in order to estimate the ܭ௔ǡ௜ at any other compressed breast thickness: 
ܭ௔ǡ௜ ൌ ݀ிௌ஽ିଶ ܻܳ         (16) 
Where ܳ is the tube current-exposure time product (mAs) for an individual image and Y is 
the x-ray tube output (mGy/mAs) for the relevant radiation quality, i.e. target/filter 
combination and tube voltage for a specific mammography unit (224). The focal point-to-
(breast) surface distance, ݀ிௌ஽, is the difference between the distance from the focus to 
breast support table minus the compressed breast thickness (224).  
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Figure 10. The ionization chamber used in the measurement of incident air kerma (Radcal 
Ion Chamber Model 10x5-6M connected to a Radcal Electrometer/Ionchamber Model 
9060 and Radcal Radiation Monitor Controller Model 9010 (Radcal Corporation, 
Monrovia, CA, USA)). Photo: Norwegian Radiation Protection Authority (NRPA). 
 
 
4.3.1 Diagnostic reference level (DRL) 
DRL is one of the most efficient and pragmatic tools used for optimization of radiological 
examinations locally in hospitals (62, 225-227). DRL is defined by the ICRP as “a form of 
investigation level, applied to an easily measured quantity, usually the absorbed dose in air, 
or tissue-equivalent material at the surface of a simple standard phantom or a 
representative patient" (228), and by the European Commission as the “dose levels in 
medical radiodiagnostic practices or, in the case of radiopharmaceuticals, levels of activity, 
for typical examinations for groups of standard-sized patients or standard phantoms for 
broadly defined types of equipment” (225).  
 
The purpose of a DRL is to trigger the first step in the optimization of patient doses (226). 
Complete optimization is concerned with maximization of risk/benefits, where the 
diagnostic outcome is relevant (229). Justification should be based upon accuracy of 
diagnosis as well as dose considerations. 
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It has been recommended to use the third-quartile values, the 75th percentile, of the 
distributions of the mean doses observed on a sample of standard-sized patients examined 
in each x-ray room as a simple indication of abnormally high doses when establishing a 
national DRL (NDRL) (226). The DRL is a useful tool in the optimization of 
mammography units, as well, and it has been proposed by a joint working party in the UK 
to base the DRL on the average MGD of MLO views for breasts with a compressed breast 
thickness of 55±5 mm (226). Further, the working party has proposed to apply a percentile 
closer to the top end of the distribution, because in mammography it is expected that the 
doses fall within a limited range. A 95th percentile has been applied in a study in Belgium 
(for SFM units) and Ireland (for FFDM units) (230-232). 
 
4.4 Method: Assessing the image quality 
4.4.1 Low contrast detectability 
In mammography it is essential to distinguish between objects with very small contrast and 
diameter. Threshold contrast tests are a common means of assessing image quality for 
noise limited imaging systems (233). An analysis of contrast detail, i.e. detecting very low 
contrast and detecting very small details, for SFM and FFDM systems is performed by 
using the CDMAM 3.4 phantom (Artinis Medical Systems B.V., PW Elst, The 
Netherlands) (Figure 11) (234-236). 
 
The image quality standard is based on contrast-detail measurements and a minimum 
standard is chosen to ensure that FFDM systems are as good as or better than current SFM 
systems (237). Software that automatically reads the phantom recordings is used (238-
240). A contrast detail curve relating object size and contrast at some fixed detection 
threshold is plotted. 
 
The CDMAM 3.4 phantom consists of an aluminium base with gold discs (99.99% pure 
gold) of varying thickness (0.03-2.00 μm) and diameter (0.06-2.0 mm) (241). The gold 
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discs are arranged in a matrix (16 rows by 16 columns). The disc diameter does not vary 
within a row, while the thickness increases (partly) logarithmically. Within a column the 
thickness of the discs is constant and the diameter increases logarithmically. Each square 
contains two discs with the same thickness and the same diameter. One is placed in the 
centre and the other in a randomly chosen corner. Easily recognizable patterns have been 
avoided. The matrix is rotated 45 degrees and the corners of the matrix are skipped. There 
are two reasons for this: a) getting a better focus on the interesting part (low contrast, small 
diameter) and b) making the recognition of the patterns more difficult. The matrix grid is 
silkscreen printed with x-ray contrasting paint. 
 
The aluminium base (0.5 mm thick Al 1050, 99.5% pure aluminium) is attached to a 
Plexiglas® cover (5 mm, PMMA). When exposing the CDMAM phantom at “normal” 
conditions (Mo anode, 30 mm Mo filter, 28 kV), the aluminium base and PMMA cover 
together have an equivalent PMMA thickness of 10 mm. The phantom is delivered with 4 
PMMA plates (each with 10 mm thickness) which are used for the simulation of different 
breast thicknesses.  
 
Contrast-detail phantoms which show objects on a uniform background may not be ideal to 
predict the performance of a system in clinical practice (138).  
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Figure 11. Photograph of the CDMAM 3.4 phantom (Artinis Medical Systems B.V., PW 
Elst, The Netherlands) consists of an aluminium base (0.5 mm thick Al 1050, 99.5% pure 
aluminium) attached to a Plexiglas® cover (5 mm, PMMA). Gold discs (99.99% pure 
gold) of varying thickness (0.03-2.00 μm) and diameter (0.06-2.0 mm) are arranged in a 
matrix (16 rows by 16 columns). Each square contains two discs with the same thickness 
and the same diameter. One is placed in the centre and the other in a randomly chosen 
corner.  
 
 
4.5 Method: Dose-risk estimates 
In the hierarchical model of efficacy proposed by Fryback and Thornbury cost-benefit 
analyses and an evaluation of number of lives saved are part of Level 6, societal efficacy 
(81). Dose-risk estimates seem to fall under Level 6 in the hierarchical model of efficacy. 
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In 2002 Preston et al. analyzed data from eight cohorts of irradiated women, and based on 
these data published an EAR model to assess the risk of radiation-induced breast cancer 
(180-182, 204-207, 242). The women included in the cohorts had been exposed to 
radiation doses ranging from 0.2 to 5.8 Gy delivered both at low and high dose-rates. 
Preston et al. stated that their analysis did not provide evidence against a linear dose-
response model in the low-dose region, for which data was missing. Their EAR model has 
subsequently been widely used to estimate the risk of radiation-induced breast cancer due 
to mammography and mammographic screening (223, 243, 244). An ERR model was used 
by Berrington deGonzales in order to estimate the potential risk of radiation-related cancer 
from screening in the UK (179), although ICRP and BEIR VII recommends using an EAR 
model when estimating the risk for the organ breast (62, 171). In 2011 Yaffe and 
Mainprize described a scheme for estimating the risk of radiation-induced breast cancers, 
breast cancer deaths, the number of lives lost, and lives saved for a variety of 
mammography screening scenarios based on Preston et al.’s model (180, 223, 242). In 
Paper V this model is applied in order to estimate the correlation between dose and risk of 
radiation-induced breast cancer. 
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5 Summary of publications 
Paper I 
Patient doses from screen-film and full-field digital mammography in a population 
based screening programme. 
Hauge IH, Pedersen K, Sanderud A, Hofvind S, Olerud HM. Radiation Protection 
Dosimetry, January 2012, Vol. 148, No. 1, pp. 65–73. Published online before print 17 
February 2011. 
Purpose 
The aim was to compare the MGD per exposure from different manufacture/models of 
SFM and FFDM systems.  
Materials and methods 
In total, 31 screening units in the NBCSP were included (24 SFM and 7 FFDM). Six 
different FFDM models from four different manufacturers (GE, Hologic, Philips and 
Siemens) were included: GE Senographe 2000D, GE Senographe DS, GE Senographe 
Essential, Hologic Lorad Selenia, Philips MicroDose Mammography D40, and Siemens 
Mammomat Novation DR. Technical parameters from approximately 50 women from the 
screening units were collected in the study period September 2006 – October 2008. Based 
on the technical parameters the MGD was estimated for the 1567 women examined at the 
31 screening units.  
Results 
The average MGD per examination was 2.84±0.08 mGy for the 24 SFM units and 
2.49±0.08 mGy for the FFDM units. The MGD per exposure was significantly lower for 
FFDM compared with SFM (CC: 1.19 versus 1.27 mGy, respectively; MLO: 1.33 versus 
1.45 mGy, respectively), but the MGD varied between manufacture/model and not all of 
the FFDM units provided lower doses than the SFM units. With the exception of the 
thinnest compressed breast thicknesses (20-29 mm), the FFDM unit Philips MicroDose 
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Mammography D40 provided the lowest MGD per exposure out of all (n=31) screening 
units. 
Conclusion 
One argument for changing from SFM to FFDM systems has been that FFDM provide a 
lower radiation dose to the screened women. Previous studies had shown that FFDM 
systems are capable of producing lower doses compared with SFM systems, but this study 
shows that changing from a SFM to a FFDM unit of any manufacture/model unit does not 
guarantee a lower MGD per exposure than SFM.  
 
Paper II 
The readout thickness versus the measured thickness for a range of screen film 
mammography (SFM) and full-field digital mammography (FFDM) units. 
Hauge IH, Hogg P, Szczepura K, Connolly P, McGill G, Mercer C. Medical Physics, 
January 2012, Vol. 39, No. 1, pp. 263-271. 
Purpose 
This study aimed to develop a simple, clinically adaptable and accurate method to measure 
the difference between the readout and measured compressed breast thickness.  
Materials and methods 
A breast thickness measuring device (TMD) was constructed. The method was comprised 
of three stages. First, a clinically realistic breast phantom and backing plate with the 
creation of a rigid torso was tested. Second, the TMD was designed and tested. Finally, 
using the TMD, the breast phantom with its backing plate was used to assess several 
mammography units/paddle combinations. The measurements were performed on different 
mammography units from three different manufacturers (GE, Hologic and Siemens). Both 
SFM and FFDM were included. This selection is representative of machines that were in 
clinical use at the time of the study. A compression of 60 and 100 N were applied. Both 
flexible and nonflexible paddles of two different paddle sizes, standard size 
(approximately: 18 cm x 24 cm (18x24)) and large size (approximately: 24 cm x 30 cm 
(24x30)), were included in the study.  
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Results 
The difference in the readout thickness and the measured thickness varies between units of 
the same model and between manufacturers. Both an over- and underestimation was found. 
Conclusion 
Individual correction factors for the readout compressed breast thickness may need to be 
established for each unit, paddle selection and applied compression force.  
 
Paper III 
Uncertainties involved in the estimation of mean glandular dose for women in the 
Norwegian Breast Cancer Screening Program (NBCSP). 
Hauge IH, Olerud HM. Radiation Protection Dosimetry, June 2013, Vol. 155, No. 1, pp. 
81-87. Published online before print 27 November 2012. 
Purpose 
In Paper II a difference in readout and measured compressed breast thickness was found 
for the different units. In Paper III the impact of the uncertainty in the compressed breast 
thickness on the MGD was examined. In addition, uncertainties in HVL, glandularity, 
kerma, and s-factor on the estimated MGD were also examined in order to obtain a broader 
view of the uncertainties in MGD.  
Materials and methods 
Estimation of MGD has been conducted by applying the method of Dance et al. (1990, 
2000, 2009). 
Results 
The largest contributions to the overall uncertainty in MGD are uncertainties in the air 
kerma (+12 %), underestimation of the thickness of +13 mm (-10.7 %), change in HVL by 
-0.05 mm (-9.0 %), overestimation of the thickness of 28 mm (+8.7 %), and changing the 
glandularity to an age-dependent glandularity distribution (+8.4 %). Uncertainties in 
thickness of approximately ±10 mm adds uncertainties in the MGD of approximately 
±10% and uncertainty in the mammographic density of ±10% will lead to an uncertainty in 
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the MGD of ±4%. The inherent uncertainty in the air kerma, given by the European 
protocol on dosimetry will add an uncertainty of 12%.  
 
Conclusion 
The total uncertainty in the MGD is estimated to be approximately 20%, taking into 
consideration uncertainties in compressed breast thickness (±10%), the air kerma (12%), 
change in HVL by -0.05 mm (-9.0%), uncertainty in the s-factor of ±2.1%, and changing 
the mammographic density to an age dependent mammographic density distribution 
(+8.4%). 
 
Paper IV 
New diagnostic reference level for full-field digital mammography (FFDM) units. 
Hauge IH, Bredholt K, Olerud HM. Radiation Protection Dosimetry, December 2013, Vol. 
157, No. 2, pp. 181–192. Published online before print 14 June 2013. 
Purpose 
In the NBCSP all units are now FFDM, and the establishment of a new DRL is called for. 
Systematic differences between categories of manufacture/models were investigated with 
respect to MGD and FOM.  
Materials and methods 
The 75th and 95th percentile were estimated for the distribution of mean MGDs for 26 
FFDM units (84%) operating in the NBCSP in 2010/2011 for the compressed breast 
thickness range 55-65 mm with the intention of establishing a national DRL.  
Results 
A large spread in MGD for the different manufacture/models is found. As national DRL 
the value 2.0 mGy is proposed, which is the 95th percentile of the dose distribution of all 
units, while the 95th percentile should be used to determine which units can be accepted for 
use for diagnostic purposes. In addition, to identify the need for optimization, we propose a 
set of manufacture/technology specific DRLs based on the 75th percentile values of the 
respective dose distributions; the value of 1.4 mGy may serve as DRL for both the GE 
Senographe Essential and Siemens Mammomat Inspiration models. 
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Conclusion 
The results in this study do however indicate that the DRL is not sufficient as a tool to 
identify units in need of optimization. The image quality, by means of FOM, defined here 
as SDNR squared divided by the MGD, should be considered as well, especially when new 
manufacture/models are introduced on the market. 
 
Paper V 
The risk of radiation-induced breast cancers due to biennial mammographic 
screening in women aged 50-69 years is minimal. 
Hauge IH, Pedersen K, Olerud HM, Hole EO, Hofvind S. Acta Radiologica, accepted for 
publication 1 November 2013. Published online before print 5 December 2013. 
Purpose 
The main aim of mammographic screening is to reduce the mortality from breast cancer. 
However, use of ionizing radiation is considered a potential harm due to the possible risk 
of inducing cancer in healthy women. The aim of the study was to estimate the potential 
risk of radiation-induced breast cancers due to organized mammographic screening as 
performed in Norway. 
Materials and methods 
We used a previously published EAR model which assumes a dose-response relationship 
in accordance with the LNT model. The estimates were calculated for 100 000 women 
aged 50-69 years, a screening interval of two years, and a follow-up until age 85 or 105 
years. Radiation doses of 0.7, 2.5, and 5.7 mGy per screening examination, a latency time 
of 5 or 10 years, and a DDREF of 1 or 2 were applied. 
Results 
The total lifetime risk of radiation-induced breast cancers per 100 000 women was 10 
(95% CI: 4-25) when the women were followed from age 50 to 85, for a dose of 2.5 mGy, 
a latency time of 10 years, and a DDREF of 1. For the same parameter values the number 
of radiation-induced breast cancer death was 1 (95% CI: 0-2). 
Conclusion 
The risk of radiation-induced breast cancer and breast cancer death due to mammographic 
screening is minimal. Women should not be discouraged from attending screening due to 
fear of radiation-induced breast cancer death. 
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6 Discussion 
Here the shift in dose level when changing from SFM to FFDM, differences in exposure 
factors for different manufacture/models, accuracy of MGD estimates, establishment of a 
DRL, and the radiation dose in the NBCSP in a dose-risk perspective will be discussed.  
 
6.1 Transition from SFM to FFDM in 
mammography 
In Paper I the transition from SFM to FFDM was studied to see the impact on the dose 
level. The ideal set-up would have been to conduct a study when only SFM units operated 
in the organized screening program, and then after the transition to FFDM, do a similar 
study with only FFDM units. Since the transition from SFM to FFDM has taken place over 
such a long period of time (from 2000 to 2011), we ended up doing a study where only a 
few FFDM units had been implemented in the program, and then comparing the dose level 
for these few FFDM units with SFM units operating in the program.  
 
One of the arguments for changing from SFM to FFDM in the NBCSP has been that 
FFDMs provide lower radiation doses than SFM units. On the other hand, in digital 
imaging it is possible to obtain higher doses than with SFM, where signal saturation would 
occur, and it is therefore particularly important to monitor the doses. In 2003 Obenauer 
conducted a phantom study which showed that the FFDM unit provided lower doses than 
the SFM unit (155). Clinical studies have supported these findings (151, 153, 154, 245). 
Hermann et al. showed that a reduction in dose of 25% is possible (153). However, these 
studies were conducted on only one FFDM system, namely GE Senographe 2000D. In a 
review from 2006 of several studies it is claimed that a reduction of 50% is possible with 
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FFDM compared to SFM (119). Although, no references to what studies these results are 
based on are given. Hendrick et al. compared radiation doses from SFM and FFDM of 
different manufacture (SenoScan (Fischer Imaging), 5000D CR System (Fujifilm Medical 
Systems USA), GE Senographe 2000D, and Lorad/Hologic CCD (charge-coupled device) 
and Hologic Lorad Selenia) and found a 28% lower MGD for FFDM than for SFM for 18 
GE Senographe 2000D units (121). Further, they found an 18.0-18.5% increase in MGD 
per view for Hologic Lorad Selenia. The increase was valid for the entire thickness range. 
When averaged over all digital manufacturers included in Hendrick et al.’s study, MGD 
per primary view was 22% lower for FFDM than for SFM, whereas the total MGD per 
woman was 17% lower for FFDM than SFM. Further, Hendrick et al. found for the GE 
Senographe 2000D that for thinner breasts the FFDM units did not provide lower doses 
than SFM, while for thicker breasts (>4 cm) GE Senographe 2000D provided lower doses 
than SFM (121). Philips uses the multislit scanning technology, which has been shown to 
perform as well as or better than SFM and provide lower doses than other systems (246-
248). For the thicker compressed breast thicknesses (≥50 mm) the MGD per exposure was 
significantly smaller for FFDM than for SFM (247). In conclusion, from these studies it 
seems that for thicker breasts FFDM systems do provide a lower dose, but not all FFDM 
are capable of providing lower doses than SFM systems. 
 
The results in Paper I showed that using FFDM does not guarantee a lower MGD per 
exposure than SFM. This is in agreement with earlier studies (119, 121, 151, 153, 154, 
245-247). Two FFDM models (Hologic Lorad Selenia and GE Senographe 2000D) 
provided an average MGD higher than four of the SFM models in Paper II (Siemens 
Mammomat 300, Siemens Mammomat 3000, Instrumentarium Alpha and GE Senographe 
DMR). Our study seems to agree with Hendrick et al.´s study for Hologic Lorad Selenia, 
but not for GE Senographe 2000D (121). The difference between our study and Hendrick 
et al.´s study is that we only had one Hologic Lorad Selenia unit and one GE Senographe 
2000D unit. We found an 18% higher MGD for GE Senographe 2000D compared to the 
average for all SFM units in our study (11% higher than for GE Senographe DMR (SFM)). 
For Hologic Lorad Selenia we found a 9% higher MGD than for the average of all SFM 
units in our study. A clinical study conducted by Hermann et al. found a MGD of 1.51 
mGy (standard deviation: ±0.34) for a GE Senographe 2000D unit (153). This represented 
a 25% lower dose for FFDM compared to SFM, when comparing their results with a prior 
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study where an overall average MGD of 2.6 mGy (range: 1.3-2.6 mGy) was found for 
SFM units, (153, 249). For GE Senographe 2000D we found a MGD of 1.57±0.06 mGy, 
which is close to what Hermann et al. found, although the average SFM was lower in our 
study than in Hermann et al.´s, ending up with different conclusions regarding if FFDM 
provide higher or lower doses than SFM. Moran et al. found a MGD of 1.88±0.01 mGy for 
a GE Senographe 2000D unit (154). This is a higher MGD than what we found in our 
study. Moran et al. compared this dose to SFM units equipped with Mo/Mo target/filter 
combinations and two types of screen film systems, fast and slow (154). They found that 
for small and intermediate compressed breast thicknesses the dose values are similar for 
the FFDM unit and for the SFM unit with slow image receptors, but much higher if 
compared with SFM with fast image receptors. For larger compressed breast thicknesses 
dose values are similar for the FFDM system and SFM with fast image receptors. In other 
words, for fast image receptors the GE Senographe 2000D did not necessarily provide 
lower doses than SFM systems.  
 
The FFDM system showed a 33% lower and a 32% higher than the third quartile of the 
entrance surface air kerma values for slow and fast screen film systems, respectively (154). 
This is in accordance with the findings in our study. Kodak Min-R 2000/Min-R 2190 is a 
faster screen film combination than Kodak Min-R EV/EV (133). In Paper I it was shown 
that even if the OD was not statistically different for the two screen film combinations 
Min-R 2000 and Min-R EV ( p = 0.844), the average MGD for the systems using Min-R 
EV (CC: 1.22 ± 0.02 mGy, MLO: 1.32 ± 0.03 mGy) was significantly smaller (CC: p = 
0.001, MLO: p < 0.001) than for the systems utilizing Min-R 2000 (CC: 1.22 ± 0.02 mGy, 
MLO: 1.32 ± 0.03 mGy) 
 
6.2 Optimization of mammography units in 
screening 
The ICRP have published three principles that are to be fulfilled in modern radiological 
protection (62). One of them is the principle of optimization. Optimization in digital 
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radiology means that only the dose level required for the medical imaging task should be 
used, and that one should refrain from using any additional dose beyond that level (250). A 
mammography unit needs to be optimized with respect to the applied target, filter and 
selected tube voltage. The selection of these exposure factors are often determined by an 
AEC termination device, and has been programmed through for instance lookup tables or 
are determined based on compressed breast thickness.  
 
In Paper I it was shown that for Hologic Lorad Selenia and GE Senographe 2000D the 
applied target/filter combinations did not agree with what has been recommended in other 
studies (201, 230). Dance et al. recommends that Mo/Mo should only be applied for 2 cm 
compressed breast thicknesses (201). The systems that use Mo/Mo were Hologic Lorad 
Selenia and GE Senographe 2000D. The Hologic Lorad unit in this study applied the 
target/filter combination Mo/Mo up to compressed breast thicknesses of 59 mm, while the 
GE 2000D unit applied Mo/Mo up to 42 mm compressed breast thickness. The target/filter 
combination is in other words applied for thicknesses much higher than what is 
recommended by Dance et al. GE Senographe 2000D had the possibility of applying the 
target/filter combinations Mo/Rh and Rh/Rh for thicker breasts, while Hologic Lorad 
Selenia had the possibility of applying the target/filter combination Mo/Rh. The results in 
Paper I showed that Hologic Lorad Selenia applied the target/filter combination Mo/Rh for 
compressed breast thicknesses down to 53 mm. By applying Mo/Rh or Rh/Rh, a lower 
dose could have been achieved at the same contrast (87, 89). By applying the target/filter 
combination Mo/Mo the obtained doses were higher than what they could have been, 
increasing the overall MGD for the FFDM units. 
 
For both Hologic Lorad Selenia and GE Senographe 2000D the optimal beam quality is 
Mo/Rh 27 kV, with the exception of the thickest and densest breasts where Rh/Rh and a 
higher kV should be used for GE Senographe 2000D and Mo/Rh 28 kV should be used for 
Hologic Lorad Selenia (230). Paper I shows that Hologic Lorad Selenia did not apply the 
target/filter combination Mo/Rh 27 kV at all (0% of the total number of exposures), while 
the target/filter combination Mo/Rh 28 kV, which is recommended for the thickest breasts 
for Hologic Lorad Selenia, was only applied once (out of 200 exposures) for a breast with 
thickness 72 mm. For the GE Senographe 2000D the target/filter combination Mo/Rh 27 
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kV (13.0% of the total number of exposures) was applied for thicknesses 41-76 mm, 
Rh/Rh 28-32 kV (53.5% of the total number of exposures) for compressed breast 
thicknesses 37-100 mm. In other words neither GE Senographe 2000D nor Hologic Lorad 
Selenia was at the time of our study using the optimal beam quality. In a clinical study it 
has been demonstrated that it is possible for the GE Senographe 2000D to lower the dose 
level, but at the same time obtain sufficient image quality (231). In conclusion, FFDM 
systems has the potential to provide lower doses, but needs to be optimized before being 
taken into use in an organized screening program. 
 
The results in Paper I did reveal that not all FFDM units in use in the NBCSP at the time of 
the study were optimized before they were taken into use. Further, it was shown that some 
mammography screening units were not optimized and an optimization should have been 
conducted before the screening units were put into use in the NBCSP. This will affect the 
dose level. In Paper IV it was shown that the dose level varies for units of the same 
manufacture/model and that an optimization of the systems with doses far from the average 
for that manufacture/model would hopefully have managed to bring that unit closer to the 
average MGD for that manufacture/model. Based on the results in Paper I and Paper IV, it 
was shown that dose surveys do reveal the need for optimization. By conducting regular 
dose surveys for all units in a screening program, it is possible to discover such differences 
between different units of the same manufacture/model and conduct optimization schemes. 
Without dose surveys, the mammography units may be operated at a less than optimal 
level. Dose surveys are therefore an important supplement to annual technical quality 
controls, where the beam quality settings for a selection of compressed breast thicknesses 
are tested. AEC testing has been shown to be one of the most important procedures (251, 
252). In conclusion, it suggests that more emphasis should be put on optimization in a 
technical quality control schema. 
 
68 
 
6.3 Factors that affect the accuracy of the 
MGD 
The radiation dose is measured for several reasons: a) to assess the performance of 
mammographic imaging equipment, b) to compare imaging systems, c) to comply with 
regulations and techniques, d) in order to perform benefit-risk analysis, and e) to answer 
questions regarding dose level from patients and physicians (68, 69). National surveys of 
radiation dose were implemented in the late 1970s (253). Accurate estimation of MGD is 
important because these estimates are used to evaluate the risk of radiation-induced 
cancers, to compare imaging systems and techniques and to assess the performance of 
mammographic imaging equipment. Inaccurate dose estimates will lead to the wrong 
conclusions when it comes to the performance of imaging systems. Here I would like to 
discuss factors that affect the accuracy of MGD estimates. 
 
The MGD is estimated according to equation (18) from the incident air kerma at the breast 
surface without backscatter and conversion factors (g, c and s). The incident air kerma is 
estimated from the point-to-(breast) surface distance, ݀ிௌ஽, according to equation (19), and 
݀ிௌ஽ relies on the compressed breast thickness. Uncertainties in the compressed breast 
thickness, as shown in Paper II, will result in uncertainties in incident air kerma. The g-
factor relies on the compressed breast thickness and HVL, while the ܿ-factor relies both on 
the mammographic density, the readout compressed breast thickness and HVL. 
Mammograms are used in order to estimate mammographic density (254-257). Further, the 
standardized mammographic density measurement for breast cancer risk analysis relies on 
accurate measurement of the compressed breast thickness (258). Inaccuracies in the 
compressed breast thickness will induce unacceptable errors in the estimation of 
mammographic density. In other words, thickness inaccuracies will lead to inaccuracies in 
the mammographic density, which will lead to inaccuracies in the c-factor. The s-factor 
relies upon choice of target/filter combination, which for some manufacturers 
(Instrumentarium, Siemens and Hologic) does rely upon compressed breast thickness. In 
conclusion, one parameter (ܿ-factor) relies on mammographic density, two parameters 
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relies on HVL, while three or all parameters, depending on the type of mammography unit 
used in the examination, relies on the compressed breast thickness.  
 
Uncertainties in the a) mammographic density, b) the readout thickness and c) the HVL 
will lead to uncertainties in the estimation of the MGD. But it seems that uncertainties in 
the compressed breast thickness will have the greatest impact, since so many of the 
parameters rely on the compressed breast thickness.  
 
Readout thickness has been shown to be inaccurate, since compression paddles may 
deform/tilt during a mammographic examination (218, 219, 221, 258, 259). This can lead 
to differences between the readout and measured compressed breast thickness of the 
compressed breast. A maximum variation of 21.1 mm in the chest wall to nipple direction 
was found by Diffey et al. (219). Further, tilt during a mammographic examination will 
affect the volumetric breast density estimation (259). But mammography units were never 
designed to provide an accurate display of the compressed breast thickness. The 
compressed breast thickness uncertainty as specified by the manufacturers can be as large 
as ±10 mm (Table I, Paper II).  
 
Methods have been proposed which provide a better estimate of the compressed breast 
thickness (218, 220-222). An accurate method using optical stereoscopic photogrammetry 
has been proposed by Tyson et al. (222). They found a variation in readout thickness with 
as much as 15 mm when compressing the same breast or phantom (222). However, the 
method developed by Tyson et al. (222) is labor intensive, being highly dependent on room 
lighting and also on image quality. In Paper II we came up with an easy method for 
measuring the compressed breast thickness, not requiring a lot of equipment. The variation 
between readout and measured compressed breast thickness seemed to vary between units 
of the same manufacture/model, urging the need to conduct corrections for each and every 
one of the units. Thus it does not seem sufficient to come up with a function for a given 
manufacture/model that would give the relation between compressed breast thickness and 
compression force for all units of the same manufacture/model. Mawdsley et al. proposed 
such functions, but from the results in our study it seems that they might only apply for one 
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specific unit (221). Our method is easy, although not as accurate as Tyson et al. (222), 
which is a weakness in the study. Also, if the compression changes over time, the 
measured compressed breast thickness will change.  
 
Hemdal (260) found that if an ionisation chamber is used, the compression paddle should 
be in contact with the chamber, otherwise the air kerma and absorbed dose will be 
underestimated due to the forward-scattered radiation from the compression paddle to the 
dosemeter. The forward-scattered contribution to the air kerma was found to be 2-10%, 
and increased with increasing compression paddle thickness and HVL. When measuring 
the air kerma, the paddle was always in contact with the ionization chamber (RadCal), and 
based on Hemdal’s work it should not be necessary to do any additional corrections. 
 
By correcting for the discrepancy between measured (real) and displayed (readout) 
compressed breast thickness, a more accurate MGD can be achieved. Uncertainties in 
compressed breast thicknesses of approximately ±10 mm will result in uncertainties in the 
MGD of approximately ±10%. In Paper IV a range in MGDs for the compressed breast 
thickness range 55-65 mm was found for Siemens Mammomat Inspiration (range: 1.18-
1.66 mGy) and GE Senographe Essential (range: 0.92-1.65 mGy). Since a correction of the 
displayed compressed breast thickness was not conducted the range in MGD could have 
been the result of a discrepancy in compressed breast thickness between the units, but 
taking a possible 10% uncertainty in the MGD into account, this does not result in the 
range in MGD as observed for Siemens Mammomat Inspiration and GE Senographe 
Essential. Since no correction in the displayed (readout) compressed breast thickness was 
conducted in Paper I and IV, it can be said that this is a weakness in these studies. 
However, it seems that a recent dose survey conducted in Ireland proceeded in the same 
manner as was conducted in Paper I and IV: they used the compressed breast thickness 
found in the Digital Imaging and Communications in Medicine (DICOM) header (44, 259). 
This does not gratify our approach of not correcting for the compressed breast thickness 
used for the different manufacture/models, but rather points to a problem in dose surveys. 
Namely, that it should be specified if a correction has been conducted or not for the 
compressed breast thickness, given the results in Paper II, where it was shown that there is 
a difference between measured (real) and displayed (readout) compressed breast thickness 
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for the different manufacture/model and even between units of the same 
manufacture/model. If such a correction is to be applied, it is important to specify what 
factor has been used. That said, since the compressed breast thickness is involved in 
determining so many of the parameters for the MGD, it would be of great help if the 
compressed breast thickness accuracy for the different manufacture/models was far more 
accurate than it actually is. That would be of tremendous help when conducting dose 
surveys where several units from different manufacture/models are included.  
 
There is one known weakness in the study presented in Paper IV. Some of the HVLs and 
radiation outputs for some of the different radiation qualities (target/filter/kV) were 
measured a long time after the collection of the exposure parameters from the women. If 
we were to do the studies all over again, we would make sure that the measurements for 
the HVLs and radiation outputs would be conducted after the collection of the exposure 
factors, in order to make sure that all HVLs and radiation outputs would be measured as 
close in time to the collection of the exposure data as possible. Gregory et al. have listed 
the numerous error sources that contribute to the uncertainty of exposure-related quantities, 
such as HVL, AEC reproducibility, MGD, and radiation output rate (261). The error 
sources that affect the measurement uncertainty of the four quantities are: a) exposure 
meter model, b) exposure meter calibration type, c) x-ray unit output, d) attenuator purity, 
e) attenuator thickness, f) attenuator increment size, g) exposure meter positioning, h) 
beam collimation, i) beam angle, j) pressure, k) temperature, l) dose conversion factor (g), 
and m) off-axis exposure. While all of them affect the MGD, only a)-j) affect the HVL and 
only a)-c), g), j) and k) affect radiation output rate. For the HVL efforts to carefully 
position exposure meters and measure and correct for beam angulation did not reduce the 
uncertainty significantly. The uncertainties of the four exposure-related quantities were 
found to be ±1.6% (HVL), ±0.0008% (AEC reproducibility), ±2.3% (MGD), and ±2.1% 
(radiation output rate) for x-ray units applying Mo/Mo. This would then add to the 
uncertainties in Paper III as well. However, the numerous error sources that contribute to 
the uncertainty of exposure-related quantities contribute less as for instance uncertainty in 
the compressed breast thickness. Also, Gregory et al. conducted their studies on Mo/Mo x-
ray beams, which are low energy. The unique error sources for these might not be the same 
as for FFDM units, for which the results in Paper I showed do apply target/filter 
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combinations of higher energy. It would be expected that the error sources would be 
smaller for higher energy. 
 
6.4 Use of diagnostic reference level (DRL) 
as a tool in acceptance testing 
The purpose of a DRL is to indicate abnormally high radiation doses and trigger the first 
step in the optimization of patient doses (226). The DRL has been and will continue to 
indicate the accepted dose level in mammographic examinations (230, 232, 262, 263). In 
general diagnostic radiology, the 75th percentile is applied for the DRL, while in 
mammography the 95th percentile has been used, arguing that the doses are much more 
optimized, and vary to a smaller extent (230). For SFM this may be true, as the detectors 
are similar and perhaps of the same manufacture (Kodak), but for FFDM different detector 
technology is available that leads to a difference in dose (Paper I).  
 
In the NBCSP a shift from SFM to FFDM has taken place over a long period of time 
(Figure 8). A new DRL for FFDM was thus needed. In Paper IV the DRL for the FFDM 
units operating in the NBCSP in 2010-2011 was found. Data were collected for 
approximately 50 women, which is in the recommended range of 10-60 women (251). The 
75th percentile is 1.4 mGy and the 95th percentile is 2.0 mGy for all units. The reason for 
estimating both the 75th and 95th percentile is that DRL is defined as the 75th percentile, but 
since a joint working group in the UK proposed using a percentile closer to the top end of 
the distribution (226), we have decided to estimate both percentiles. In a study in Belgium 
where the DRL was estimated for SFM units, the 95th percentile was applied, arguing that 
the doses were expected to be quite similar due to extensive quality assurance for 
mammography units (230, 231). In Paper IV we found that the average MGD for different 
manufacture/model (GE Senographe DS, GE Senographe Essential, Hologic Lorad 
Selenia, Hologic Selenia Dimensions, Philips L30 and Siemens Inspiration) ranges from 
0.69 to 2.11 mGy, a range of 1.42 mGy, for the compressed breast thickness interval 55-65 
mm. The highest MGD was 206% larger than the smallest MGD. This is quite a large 
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range, and due to the difference in technology, it might be a better idea to separate the 
manufacture/models from each other and evaluate the units within each category of 
manufacture/model. As national DRL the 95th percentile, 2.0 mGy, is proposed, but in 
order to identify the need for optimization, we propose a set of manufacture/technology 
specific DRLs based on the 75th percentile values of the respective dose distributions. This 
will take into consideration the difference in dose level between the manufacture/models 
and better identify those units that are in need of optimization for each manufacture/model. 
Only Siemens Mammomat Inspiration and GE Senographe Essential were represented with 
several units, and therefore it was only possible to establish technology specific DRLs 
based on the 75th percentile values for these two manufacture/models; the value for both 
being 1.4 mGy.  
 
In the NBCSP there are multiple units from GE Senographe Essential and Siemens 
Inspiration, enabling a comparison of MGD and FOM between these units. A study has 
been conducted comparing GE Senographe DS and GE Senographe Essential detectors, 
finding that GE Senographe DS showed statistically significant poorer detection ability 
than GE Senographe Essential (264). Overall, for the FOM we also found that the GE 
Senographe DS unit provided a lower FOM than the GE Senographe Essential units. 
Further, the results in Paper IV showed that there is a large variation in FOM for the GE 
Senographe Essential units, compared to the Siemens Mammomat Inspiration units, for 
which the FOM seems to vary less for the different units. Such a large variation in FOM 
indicates that an optimization might be needed for some of the units. Based only on the 
DRL (either the 75th or 95th percentile) this was not so apparent. The results in Paper IV 
showed that three Siemens Mammomat Inspiration and two GE Senographe Essential had 
an average MGD above the 75th percentile. Further, it was shown that one Siemens 
Mammomat Inspiration and one GE Senographe Essential had an average MGD above the 
95th percentile. Applying the 95th percentile would then only indicate that one GE 
Senographe Essential was in need of optimization, while from the large difference in FOM 
for GE Senographe Essential units one might think that more of them were in need of 
optimization. Using only the DRL as a means of optimization criteria, one might miss out 
on the other units in need of optimization.  
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The results in Paper IV do indicate that the DRL is not sufficient as a tool to identify units 
in need of optimization. This is in agreement with Svahn et al., who have also shown that 
the radiation dose and performance (as described by the FOM) should not be evaluated 
independently (46). The FOM, defined as SDNR squared divided by the MGD, should be 
considered as well, because the results in Paper IV show that those units with high FOMs 
do not necessarily have low MGDs, and those units with low FOMs do not necessarily 
have high MGDs. Zdesar has published reference levels for image quality, in the form of 
contrast index values, where contrast index is defined as the difference in OD between 
100% glandular and 100% fatty regions of a phantom image (265). The mammography 
units included were mainly SFM units. Zdesar ranged the units from worst to best contrast 
index, and the first quartile is used as a reference level (265). For the SFM units no 
correlation between contrast index and MGD was found. Zdesar conclude that this might 
be due to the fact that after the optimal mean OD is reached, contrast depends on other 
parameters than the dose (mainly on material and the film-developing process). It might be 
that one could establish reference levels for the FOM for the different manufacture/models, 
setting a minimum value for the FOM. Any unit having a lower FOM would have to go 
through optimization. This would combine a measurement for both the image quality and 
the MGD.  
 
In Paper IV we included results from CDMAM tests conducted during the annual quality 
controls, which may only give a momentary view of the situation if the image quality 
measurements differ significantly from day to day. However, in an earlier study it has been 
shown that the measured threshold contrast values are reasonably stable (maximum: 10%), 
only with some random variations (266). This implies that the estimations are pretty stable, 
and that the results shown in Paper IV can be used to make general conclusions about each 
of the units. 
 
6.5 Radiation doses in a dose-risk perspective 
Mammography is associated with a small dose of ionizing radiation, which is seen as a 
disadvantage in mammography screening due to the potential risk of radiation-induced 
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cancer. In its 2007 recommendations ICRP increased the tissue weighting factor for breast 
from 0.05 to 0.12 in the light of recent epidemiological findings and the focus on cancer 
incidence in the detriment calculations (62, 195). Since the NBCSP are inviting 
asymptomatic women to screening, it is therefore particularly important to follow the 
ALARA principle. This is achieved with annual quality control and surveillance of the 
dose level. In order to evaluate the NBCSP as a whole one of the aspects that need to be 
evaluated is the dose level and the risk of radiation-induced breast cancers. In order to 
estimate absolute risks we need to apply the models that are currently used for estimating 
the dose. In Paper V an estimation of the risk of radiation-induced breast cancers, breast 
cancer deaths, the number of lives lost and lives saved has been conducted with Preston et 
al.`s model and a schema developed by Yaffe and Mainprize (180, 223). The uncertainty in 
the model is in the order of 40%. This is reflected in the width of the confidence intervals 
for risk estimates in Paper V. Here, the results in Paper V, the model in itself, and what is 
known from epidemiologic and cell studies for the dose level applied in mammography 
will be discussed. 
 
When applying a model that assumes an LNT relationship, we found that one death (95% 
confidence interval: 0-2) in 100 000 women might be induced by radiation when the 
women were followed from age 50 to 85, exposed to a dose of 2.5 mGy, assuming a 
latency time of 10 years, and applying a DDREF of 1. Of approximately 7900 breast 
cancer incidences it is possible that 0.05–0.3% of the cases may be due to mammographic 
screening. One death per 100 000 has been categorized as a minimal risk (267). We 
therefore concluded that radiation doses in the NBCSP are of minimal risk to the women 
attending the NBCSP. 
 
The latency time and DDREF are both factors that influences on the risk estimate. Earlier 
studies have applied a latency time of 10 years when assessing the breast cancer risk (208, 
223), and we decided to apply a latency period of 5 and 10 years, which seemed to be 
consistent with earlier studies (171, 174, 201, 268). In attempting to estimate lifetime 
population risks it is important to predict how risk vary as a function of time after radiation 
exposure. In Paper V, for a dose of 2.5 mGy and a DDREF of 1, a latency time of 5 years 
resulted in a higher estimate for the number of radiation-induced breast cancers than a 10 
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year latency time did, 13 (range: 6-31) versus 10 (range: 4-25), respectively. A longer 
latency time, will result in fewer radiation-induced breast cancers. Further, we applied a 
DDREF of both 1 and 2, in consistency with UNSCEAR, although higher values for the 
DDREF has been found (174). Also, it has been suggested that the DDREF decreases with 
decreasing energy (269). But there are large uncertainties, and the choice of DDREF will 
influence the dose estimates: a shift to a higher DDREF will reduce the number of 
radiation-induced breast cancers. 
 
In the cohort data that Preston et al. included in their analysis the mean age for the study 
population was 27 years (range: 13 – 44 years). This is substantially lower than the 
screening population in Norway, which is 50-69 years. Sensitivity to ionizing radiation is 
known to decrease with age (174). An overestimation of radiation-induced breast cancers 
and breast cancer deaths is therefore expected in our study. 
 
Quantitative information on the risk of cancer in human populations exposed to ionising 
radiation comes largely from information available from groups exposed at intermediate 
and high doses and dose-rates (185). This is also the case for the model published by 
Preston et al. They established their model based on radiation doses 8-20 000 times (0.02-
50 Gy) larger than the current MGD per examination (2.5 mGy) for women in the NBCSP 
(180). The doses in the cohort studies which Preston et al. based their model on were 
applied at low and high dose-rates. For radiation protection purposes, however, it is thus 
necessary to estimate the influence of low doses delivered at low dose-rates on cancer 
induction (185). However, mammography is considered to be a low dose (<100 mGy) and 
high dose-rate examination (>12 Gy/h (=3.33×10-3 Gy/s) (121, 212, 270, 271). In the 
NBCSP the dose-rate for the target/filter combination Mo/Mo and 28 kV for 27 screening 
units (16 Siemens Mammomat Inspiration, one GE Senographe DS and nine GE 
Senographe Essential) is found to be in the range 39-60 Gy/h (=1.1-1.7×10-2 Gy/s). Cancer 
induction in mammography, thus, has to be estimated based on the fact that mammography 
is a low dose and high dose-rate examination. A prior study has shown that for doses of 1 
Gy or higher, in other words high doses, delivered at high dose-rates (2.2 10-2 Gy/s (=78 
Gy/h)) the frequency of chromosome aberrations with respect to the radiation dose is non-
linear (272). When non-linearity is found for high doses and high dose-rates, there is 
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reason to question the validity of a linear model at low dose and high dose-rate. In other 
words, it might be suspected that non-linearity is present at low dose and high dose-rate.  
 
Studying dose-risk relationship in an epidemiological approach is almost impossible due to 
the high number of persons exposed to ionizing radiation and the follow-up time needed 
(187, 201). A recent large population based study on CT scans shows the overall cancer 
incidence was 24% greater for exposed than for unexposed persons for all types of cancer 
(273). For all cancers, except brain cancers after brain CT the average effective dose per 
scan was approximately 5 mSv. For brain cancers after brain CT (brain exposures) the 
average brain dose per scan was approximately 40 mGy, while for leukaemias and 
myelodysplasias (all exposures) the average red bone marrow dose per scan was 
approximately 5 mGy. For breast cancer, however, no separate increase in the incidence 
rate ratio can be found (incidence rate ratio: 0.99 (95% CI: 0.83-1.17)) (273). This leads us 
to think that when doses in the range 5-40 mGy does not lead to an increased risk of breast 
cancer, it is not likely that doses below this range will imply an increased risk. Since 
mammography typically provides average doses of 2.5 mGy, which is below the range 5-
50 mGy, it may be that there is no increased risk in this dose area. 
 
For studies on laboratory animals, 64% of the 262 experiments reviewed did not show any 
linear dose relationship for doses 0.04 Gy-40 Gy (274). The dose-response curve was 
either J-shaped, hockey-stick-like, or with no discernible effect. Studies on cells are not 
conclusive in how cells respond to radiation, but it is known that the cellular responses at 
low doses differ from those at high doses (189, 213, 214, 275-277). Beyreuther et al. has 
found that for energies below 50 keV, which are typically relevant for mammography, 
increased chromosomal aberrations frequencies take place (278). 
 
The use of the LNT model is controversial for low doses where the LNT model has lacked 
to show validity and the debate continues (279, 280). Deterministic effects has been 
observed for doses from 0.2 Gy and upwards, but below this dose there is not consistency 
in the data (279). By applying a model that assumes a LNT relationship an unwarranted 
fear about ionizing radiation may occur (280). A study has shown that 59% of doctors 
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identified fear as a major reason for their patients` refusal of mammography examinations 
(281). Based on the findings in Paper V and similar studies, such fear seems to lack 
support. It is important to inform the women that the risk is minimal, and that the radiation 
dose should not be considered as a reason for refraining from a mammography 
examination. 
 
The model applied in Paper V has been applied by others when estimating the risk of 
radiation-induced breast cancers in mammography, and therefore it was decided to use this 
model in our estimations of the risk of radiation-induced breast cancers. However, the 
model is connected with large uncertainties: a) the assumption of linearity in a dose area 
for which data are missing and b) inherent uncertainty in the model due to statistical 
uncertainty in the data on which the model is based. In addition, there is increasing 
evidence of non-linear responses of biological systems to low radiation doses delivered at 
low dose-rates, resulting in doubts concerning extrapolations from high doses and high 
dose-rates as well (194). The topic of biological effects and risks of low doses of ionizing 
radiation is an on-going debate, and it has turned out to be the longest running debate in the 
radiation sciences. In other words, more research is needed in order to make any 
conclusions as to the effects at low doses. Until a new model for low doses and high dose-
rates has been proposed it is difficult to make better estimations regarding the radiation-
induced risk. The estimates in Paper V are to be considered as the best estimate that one is 
able to make with the current knowledge. The LNT model is used worldwide for radiation 
protection regulations. In ICRP Publication 99 it is stated that: “The report concludes that 
while existence of a low-dose threshold does not seem to be unlikely for radiation-related 
cancers of certain tissues, the evidence does not favour the existence of a universal 
threshold. The LNT hypothesis, combined with an uncertain DDREF for extrapolation 
from high doses, remains a prudent basis for radiation protection at low doses and low dose 
rates.” (282) This might result in an overestimation of the risk, but according to ICRP it is 
better to err on the safe side. It is important to use the estimates with caution, though. In 
order to make more accurate estimations, a new model must be founded on both 
epidemiological data and biological mechanisms (194).  
 
79 
 
6.6 Cost-benefit: An evaluation of the 
NBCSP 
In order to legitimize a screening program the benefits needs to exceed the associated risks 
(283). This is the principle of justification (62). In an evaluation of the benefit-risk (or 
cost-benefit) the advantages and disadvantages of screening need to be weighed up against 
each other (54). Breast cancer screening has been shown to be cost-effective in Norway 
(284, 285). Given the results in Paper V we found the risk to be minimal. In the NBCSP 
one in every 5 women (20%) will be recalled for further assessment with a negative 
outcome. In comparison to other European screening programmes, where a pooled 
estimate 19.7% was found (286), this seems to be in the high end of this range. The 
interval cancer rate is 18.2 per 10 000 screens in the NBCSP (287), which is higher than 
recommended in the European Guidelines. The elevated rate in the second part of the 
interval may be explained by the definition, the use of the background incidence from an 
earlier time period without adjusting for temporal increases as discussed above, a 
somewhat low screening detection rate, and the possibility of opportunistic screening in the 
interval between two screening sessions in the NBCSP. No reliable estimates for 
overdiagnosis were available for the NBCSP (288). The unadjusted or incompletely 
adjusted estimates ranged from 37% to 54% in Norway. For other screening programs in 
Europe the most plausible estimates of overdiagnosis range from 1% to 10%. In 
conclusion, it might be that the numbers for false positives and interval cancers are in the 
high end compared to the rest of the screening programmes in Europe. Given that the 
estimates of overdiagnosis are undecided, and that the risk of radiation-induced breast 
cancer is minimal there are in other words two factors out of four that seems to be a great 
disadvantage for the NBCSP. On the other hand, recently a mortality reduction of 43% was 
reported from the NBCSP (21). This should be considered a large benefit in a screening 
program. 
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7 Conclusion 
Previous studies have shown that FFDM systems are capable of producing lower doses 
compared with SFM systems, but the results in this thesis shows that using FFDM does not 
necessarily guarantee a lower MGD per exposure than SFM. FFDM do provide lower 
doses for larger compressed breast thicknesses, but for the thinner breasts no significant 
difference is found (Paper I). 
Estimating the MGD depends on the compressed breast thickness. The difference in the 
readout thickness and the measured thickness varies between units for the same model and 
between manufacturers. Any corrections to compressed breast thickness need therefore to 
be performed for the unit in question (Paper II). 
Difference between readout thickness and the measured thickness implies uncertainties in 
the estimation of the MGD. Uncertainties in thickness of approximately ±10 mm adds 
uncertainties in the MGD of approximately ±10% and uncertainty in the glandularity, due 
to uncertainty in the compressed breast thickness, of +/-10% will lead to an uncertainty in 
the MGD of -/+4% (Paper III). 
The DRL does not seem sufficient as a tool to identify units in need of optimization. The 
image quality by means of FOM, defined here as SDNR squared divided by the MGD, 
should be considered as well, especially when new manufacture/models are introduced to 
the market (Paper IV). 
For women screened according to the schema used in the NBCSP, the risk of radiation 
induced breast cancer and breast cancer death is minimal (Paper V). 
Asymptomatic women are being screening, and it is therefore important to fulfil the 
ALARA principle. Radiation protection in the form of optimization with respect to dose 
and image quality will have an effect on the diagnostic outcome. 
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Abstract 
Background: The main aim of mammographic screening is to reduce the mortality from breast 
cancer. However, use of ionizing radiation is considered a potential harm due to the possible 
risk of inducing cancer in healthy women.  
Purpose: To estimate the potential number of radiation-induced breast cancers, radiation-
induced breast cancer deaths, and lives saved due to implementation of organized 
mammographic screening as performed in Norway. 
Material and Methods: We used a previously published excess absolute risk model which 
assumes a linear no-threshold dose-response. The estimates were calculated for 100 000 
women aged 50-69 years, a screening interval of two years, and with an assumed follow-up 
until age 85 or 105 years. Radiation doses of 0.7, 2.5, and 5.7 mGy per screening 
examination, a latency time of 5 or 10 years, and a dose and dose-rate effectiveness factor 
(DDREF) of 1 or 2 were applied. 
Results: The total lifetime risk of radiation-induced breast cancers per 100 000 women was 10 
(95% CI: 4-25) if the women were followed from age 50 to 85, for a dose of 2.5 mGy, a 
latency time of 10 years, and a DDREF of 1. For the same parameter values the number of 
radiation-induced breast cancer death was 1 (95% CI: 0-2). The assumed number of lives 
saved is approximately 350. 
Conclusion: The risk of radiation-induced breast cancer and breast cancer death due to 
mammographic screening is minimal. Women should not be discouraged from attending 
screening due to fear of radiation-induced breast cancer death. 
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Introduction 
Mammographic screening is proved to reduce mortality from breast cancer (1). However, it is 
still debated whether the benefits outweigh the harms. Use of ionizing radiation is considered 
a potential harm due to the possible risk of inducing cancer in healthy women (2-4).  
It is generally agreed that ionizing radiation at high doses (>100 milligray (mGy)) and high 
dose-rate (>0.1 mGy/min) has the potential to induce cancer (5, 6). Mammography is 
considered a low dose and high dose-rate examination (7). Radiation risk at low doses is 
commonly extrapolated from the risk at high doses (8). Extrapolation from high to low doses 
can be performed by a linear extrapolation (linear no-threshold (LNT) model), with a 
downward or upward curving line/pointing curve, with a threshold linear model, or with a 
hormetic model (8, 9). In 2002 Preston et al. analyzed data from eight cohorts of irradiated 
women (3, 10). The radiation doses included in the analysis ranged from 0.2 to 5.8 Gy 
delivered both at low and high dose-rates. For both the region where Preston et al. had data, 
and for the low dose region where data was missing, they stated that their analysis did not 
provide evidence against a linear dose-response model. Their excess absolute risk (EAR) 
model has subsequently been widely used to estimate the risk of radiation-induced breast 
cancer due to mammography and mammographic screening (2, 4, 11).  
In 2011 Yaffe and Mainprize described a model for estimating the risk of radiation-induced 
breast cancers, breast cancer deaths, the number of lives lost, and lives saved for a variety of 
mammography screening scenarios (2). However, biennial screening for the age group 50-69 
years, as recommended by the European guidelines for breast cancer screening and diagnosis, 
was not included in their estimates.  
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The Norwegian Breast Cancer Screening Program (NBCSP) is a population based screening 
program offering women aged 50-69 years two-view mammography every two year (12). The 
program started as a pilot in four counties in 1996 and became nationwide in 2005. It is run 
according to the European guidelines. We wanted to apply the model developed by Yaffe and 
Mainprize on data collected as a part of the quality assurance of the NBCSP to estimate the 
potential number of radiation-induced breast cancers, radiation-induced breast cancer deaths, 
and lives saved due to implementation of the NBCSP. 
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Materials and method 
Dose data collected in the NBCSP was used in the study (13). The program started in four 
counties in 1996 and became nationwide in 2005. The NBCSP offers women aged 50-69 
biennial mammography screening. No ethical committee approval was necessary since we 
used aggregate data without linkage to the individual women. 
We adopted the model of Yaffe and Mainprize (2) and estimated the expected number of 
radiation-induced incidences, radiation-induced deaths, and number of lives saved per 
100 000 women in a scenario where the women started to undergo mammographic screening 
at age 50 years and received a total of ten screening examinations at two-year intervals. The 
women were followed for radiation-induced breast cancer and breast cancer death until age 85 
and 105 years, which are the expected average age and maximum age of death for women in 
Norway in 2011, respectively (14)..  
The parameters a) radiation dose per examination, b) the latency period for developing breast 
cancer, and c) dose and dose-rate effectiveness factor (DDREF) were input values in the model 
(2). Three different dose values were chosen for estimation of lifetime risks; 0.7, 2.5, and 5.7 
mGy. The specific values were chosen as a result of a previous study from the NBCSP where an 
average mean glandular dose (MGD) for full-field digital mammography was found to be 2.5 
mGy (range: 0.7 - 5.7 mGy) per screening examination (13). Latency times of 5 and 10 years 
were applied (5).  
The DDREF is applied to correct for possible reduction in risk of radiation-induced cancers at 
low dose or low dose-rate compared to high dose and high dose-rate exposure (15). A value 
equal to 1 implies no correction, while a value larger than 1 implies a lower risk. The National 
Academy of Sciences (NAS) Biological Effects of Ionizing Radiation (BEIR) report, NAS 
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BEIR VII, recommends a value of 1.5 (15), while the International Committee on Radiation 
Protection (ICRP) considers a value of 2 to be appropriate (9). In the present study, a DDREF 
of 1 and 2 were applied. 
Number of radiation-induced breast cancer cases 
The number of radiation-induced breast cancers, ஼ܰሺܣሻ, was estimated as (2): 
஼ܰሺܣሻ ൌ ܯሺܣ஻ǡ ܣሻ ෍ ܧܣܴሺܣ௑ǡ ܣǡ ܦሻ
஺ಶ
஺೉ୀ஺ಳ
 
ܯሺܣ஻ǡ ܣሻ is a life-table correction  which provides the probability that a woman alive at age 
ܣ஻, the age at which screening starts, is still alive at age ܣ௫, the age at which the woman is 
exposed to radiation (here: 50-69 years), is able to participate in the screening program, and is 
alive at age ܣ, the age at which the radiation-induced breast cancer develops (16). The life-
table correction for women is used to account for deaths (D) due to other causes than 
radiation-induced breast cancer.  
The excess absolute risk (EAR) per year of developing a radiation-induced breast cancer per 
10 000 woman years (ܹܻ) per radiation dose (ܩݕ) for women at age ܣ (50 years and older) 
was estimated as (3, 10): 
ܧܣܴ
ͳͲͲͲͲܹܻܩݕ ൌ ͳͲ݁
ି଴Ǥ଴ହሺ஺ೣିଶହሻሺ ܣͷͲሻ 
The maximum value for A was either 85 or 105 years. The total lifetime risk was estimated 
for women aged 50-69 years who attended biennial screening, i.e. ten examinations, by 
summing the values for each of the ܣ௫ values in the stated range.  
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Number of radiation-induced breast cancer deaths 
The number of deaths from radiation-induced breast cancer, ஽ܰሺܣ஽ሻ, at age of death ܣ஽, was 
estimated as (2):  
஽ܰሺܣ஽ሻ ൌ ෍ ஼ܰሺܣሻܯሺܣǡ ܣ஽ሻሾܵሺܣǡ ο െ ͳሻሿሾܵሺܣǡ ο െ ͳሻ െ ܵሺܣǡ οሻሿ
஺ವ
஺ୀ஺ಳା௅
 
஼ܰሺܣሻ is the number of radiation-induced breast cancers. ܯሺܣǡ ܣ஽ሻ is a life-table correction, 
which provides the probability that a woman alive at age ܣ is alive until age ܣ஽. ܵሺܣǡ οሻ is the 
probability of surviving a number of years, Δ, after detection of breast cancer at age ܣ, where 
Δ=(ܣ஽-ܣ). ܵሺܣǡ ο െ ͳሻ is the probability that a woman will survive until ܣ஽ minus one year 
after the cancer is detected, but not to age ܣ஽ (2). For ܵ, adjusted survival-rates for women 
screened in the NBCSP from 1996 to 2009, provided by the Cancer Registry of Norway, were 
used. ஼ܰሺܣሻ and ஽ܰሺܣ஽ሻ are estimated with 95% confidence intervals as described by Yaffe 
and Mainprize (2). 
 
Number of lives saved 
The expected number of breast cancer deaths without screening is estimated from the breast 
cancer incidence (Table 1) by making a life-table correction and summing the numbers that 
arise each year (16). The life-table correction takes into account the number of expected 
deaths. The estimation was conducted with cut offs at 85 and 105 years. The estimation of the 
breast cancer mortality without screening is conducted in the same manner as the estimation 
of radiation-induced breast cancer deaths, except that a survival curve for an unscreened 
population is applied. 
9 
 
The number of lives saved is estimated as the difference between the expected number of 
breast cancer deaths with ( ஽ܰǡ௪௜௧௛) and without ( ஽ܰǡ௪௜௧௛௢௨௧) screening (2). The expected 
number of breast cancer deaths with screening is estimated as the expected number without 
screening, multiplied with the expected mortality reduction, ܯ௥௘ௗ, due to screening. We 
applied a mortality reduction of 43% as reported recently from the NBCSP (17). The number 
of lives saved is expressed as: 
ܰݑܾ݉݁ݎ݋݂݈݅ݒ݁ݏݏܽݒ݁݀ ൌ ஽ܰǡ௪௜௧௛௢௨௧ െ ஽ܰǡ௪௜௧௛ ൌ  ஽ܰǡ௪௜௧௛௢௨௧ െ ൫ ஽ܰǡ௪௜௧௛௢௨௧ ൈ ܯ௥௘ௗ൯ 
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Results 
Lifetime risk of radiation-induced breast cancer for the various combinations of the input 
parameters (dose, latency time, and DDREF) used in the model has been estimated (Table 2). 
The estimates are based on biennial mammographic screening in women aged 50-69 years if 
followed until age 85 or 105 years. The lifetime risk of radiation-induced breast cancers per 
100 000 women was 10 (95% CI: 4 - 25) when a radiation dose of 2.5 mGy, a latency time of 
10 years, and a DDREF of 1 were used (Table 2). If followed until 105 years, the risk is 13 
(95% CI: 5 - 34).  
For the same parameter values, the lifetime risk for radiation-induced breast cancer deaths per 
100 000 women was estimated to be 0.8 and 1.0 (range: 0.3-2.7) if followed until age 85 and 
105 years, respectively.  
The expected number of breast cancer deaths without screening, is found by applying the 
breast cancer incidence from 2010 (in other words while the NBCSP was running). A 43% 
reduction in breast cancer mortality is applied, as found as an effect of attending the NBCSP 
(17). Lives saved are found to be 395 and 415 if women aged 50 years are followed until age 
85 and 105 years, respectively. Using the breast cancer incidence from 1995 (before the 
NBCSP started) resulted in 339 and 362 lives saved with a cut-off at 85 and 105 years, 
respectively. 
  
11 
 
Discussion 
Depending on the parameter values (radiation dose, latency time, DDREF), we estimated 
between 1 and 30 breast cancers to be induced by ionizing radiation if 100 000 women aged 
50-69 years were screened biennially ten times for breast cancer and if they were followed 
until age 85 years. The number of radiation-induced breast cancer deaths was estimated to 
range from zero to 3 for the same parameter values and same cohort of women. In accordance 
with the Health Protection Agency in the United Kingdom risk of this order of size is 
considered to be minimal (18).  
In 1995, before the NBCSP started, 1548 breast cancers were detected among the 703 122 
women aged 50-85 years residing in Norway, i.e. a breast cancer-rate of 220 per 100 000. If 
we assume an incidence rate of 220/100 000 during a time-span of 36 years (from age 50 to 
85 years) we will have 7920 breast cancer cases (220 × 36) among 100 000 women. The 
number of radiation-induced breast cancers in our calculations for the same time-span was 
0.13% (10/7920) of the estimated breast cancer cases diagnosed for this group of women in 
the described scenario. The percentage of radiation-induced breast cancer deaths is even 
smaller. 
Yaffe and Mainprize estimated 86 radiation-induced breast cancers and 11 breast cancer 
deaths in women aged 40-74 years, while de Gelder et al. estimated 8 breast cancers and 2 
breast cancer deaths in women aged 50-74 years (2, 4). We applied a similar model as Yaffe 
and Mainprize and de Gelder et al., but the outcome in our study differed from their estimates. 
These discrepancies were expected due to different screening intervals, age groups, and 
parameter values used in the estimations.  
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However, these estimates have several limitations and only represent a rough estimate. The 
expected number of breast cancer cases is probably underestimated, which will result in an 
overestimation of the percentage of radiation-induced breast cancer cases and deaths. 
In addition, the LNT hypothesis assumes linearity of the dose-response relationship for cancer 
induction in general, even at low doses (19). This implies that even a small dose of radiation 
is assumed to represent an increased risk of cancer in humans (15, 20). Because the dose-
response curve could not be determined at low dose level, the LNT model was originally used 
to provide an upper limit of risk, with zero as the smallest risk value for low dose levels (21). 
The LNT model has several limitations and its validity is debated (2, 3, 20, 22-25). A 
protective effect at low doses, hormesis, is even suggested (22, 25). Significant fluctuations 
are shown in the estimated risk of induced cancers in studies with low ionizing radiation doses 
(20, 26-28). Studies are not conclusive in how cells respond to ionizing radiation, but it is 
known that the cellular responses to low doses differ from those that to high doses (20, 29, 
30). In practice it is impossible to draw conclusions regarding the shape of the curve 
describing the dose-risk relationship with the knowledge available today. 
The LNT model is considered to be the “best practical approach to managing risk” from a 
radiation protection point of view, despite of its known limitations (8, 9, 29). The “better safe 
than sorry” approach is debated (26, 31, 32), but scientific committees like the ICRP maintain 
that it is better to err on the side of caution (9). This approach is also supported in a report by 
BEIR VII (15). On the other hand, the French National Academies of Science and Medicine 
concluded that the LNT model lacks justification for doses from 0.2 to 5 Gy (33). 
The EAR model used in this study has an inherent uncertainty of about 40% (3). The model 
was based on a pooled analysis of eight cohorts. Only one of the cohorts showed significantly 
increased risk of breast cancer for doses lower than 0.02 Gy. In addition, the mean age for the 
13 
 
study population was 27 years (range 13 – 44 years), which is substantially lower than the 
screening population in Norway. Sensitivity to ionizing radiation is known to decrease with 
age (15, 18, 34). The latter factor make us expect an overestimation rather than an 
underestimation of the number of radiation-induced breast cancers and breast cancer deaths in 
our study (32, 34). 
In conclusion, using the LNT-model resulted in 30 or less radiation-induced breast cancers if 
100 000 women aged 50-69 years were screened biennially ten times and if they were 
followed for breast cancer until age 85 years. The estimated number of radiation-induced 
breast cancer deaths was 3 or less, compared to the assumed number of lives saved of 
approximately 350. It should thus be safe to conclude that the risk of radiation-induced breast 
cancer and breast cancer death as a result of organized screening is considered minimal when 
applying a screening program according to the European guidelines. 
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